Ibogaine safety and risk management

Before Treatment

Candidate evaluation, preparation, consent, and readiness.

Educational material; not a treatment relationship.

Heart rhythm demo

1 Candidate Evaluation

2 Pre Treatment Optimization

Assessment, consent, and team preparation

Define responsibilities, establish the participant’s history and goals, and document voluntary informed participation.

Editorial illustration

Image context

Illustrative editorial image: pre-treatment consultation and preparation. Not a clinical case photograph.

Practitioner and Facilitator Knowledge Core

Knowledge domains, role boundaries, and the know, recognize, support, escalate competency matrix.

A competent ibogaine team needs more than cardiac monitoring. The people closest to the participant should understand the drug timeline, withdrawal, vestibulocerebellar effects, physical dependency created by ataxia, movement sensitive nausea, sensory and relational vulnerability, cultural context, and the point at which supportive presence must give way to medical escalation. Clinical authority and facilitator skill are complementary roles, not interchangeable credentials.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

Knowledge domain	What the team needs to understand	Role boundary
Ibogaine and noribogaine Safety Relevant Pharmacology and Pharmacokinetics Product Identity and Formulation Observed Human Exposure and Dose Context	Expected time course, metabolic variability, common effects, delayed physiology, formulation differences, and limits of the evidence.	Facilitators should know what may be expected; prescribing and dose decisions remain with qualified clinicians.
Cardiac and medical safety Cardiovascular Evaluation Medication and Interaction Review Cardiac Risk Modifiers Change Detection: What Changes the Plan?	QT risk, bradycardia, interacting drugs, electrolyte vulnerability, symptoms that change the plan, and the emergency pathway.	Nonmedical staff need recognition and escalation competence, not independent ECG diagnosis.
Substance use and withdrawal Substance Use History Continuing Addiction Care	Last use, tolerance, withdrawal trajectory, alcohol and benzodiazepine danger, opioid relapse and overdose risk.	Withdrawal treatment plans remain clinician owned.
Ataxia and vestibular effects Distinguishing Vertigo, Ataxia, Disequilibrium, and Presyncope Ataxia, Vertigo, Movement Sensitivity, Nausea, and Physical Vulnerability	Severe gait impairment, tremor, dizziness or vertigo-like experience, movement sensitivity, falls, toileting and transfer needs.	Every person providing direct support should know how to assist mobility without creating unnecessary movement.
Nausea, vomiting and airway Nausea and vomiting Respiratory, Airway, and Aspiration Safety Persistent Vomiting / Aspiration	Motion can intensify nausea in some participants. Vomiting creates aspiration, dehydration, electrolyte and medication questions.	Comfort measures must never delay assessment of persistent or complicated vomiting.
Sensory environment Sensory and Relational Containment	Light, sound, touch, movement, alarm noise and staff traffic can become unusually intense.	Reduce nonessential stimulation while preserving medically necessary monitoring.
Relational safety Transient Persecutory Mistrust: When the Room Feels Like the Enemy Delirium / Prolonged Altered Mental Status	Trust can change quickly. Explain actions, preserve choices where safe, avoid crowding, and know how to respond when caregivers are temporarily perceived as threatening.	Support does not mean validating persecutory or metaphysical claims as fact.
Phenomenology and meaning Phenomenology and Experiential Safety Visionary Intensity, Orientation, and Grounding	Visionary content can be absent, symbolic, autobiographical, frightening, spiritual, dissociative, or difficult to describe.	Do not force interpretation during peak impairment. Preserve participant authorship.
Touch, toileting and dignity Touch, privacy and toileting Supporting the Participant Through the Acute Experience	Ataxia may make the person dependent for basic care while awareness remains intact.	Consent, privacy, explanation, and minimal necessary exposure remain part of safety.
Culture and traditional knowledge Historical and Cultural Orientation for Facilitators Traditional and Community Knowledge	Iboga, purified ibogaine, community treatment, and Bwiti practice are not interchangeable categories.	Do not imply lineage, initiation, or authorization that is not actually present.
Post acute recovery Prolonged Supportive Care: Comfort, Toileting, Nutrition, and Rest Extended Observation Discharge Readiness Continuing Addiction Care	Sleep, hydration, nutrition, mobility, mood, beliefs, medication restart, withdrawal, relapse risk and support network can continue to change after the visionary phase.	Do not use the end of visions as the end of care.
Documentation and handoff Documentation Standard Staffing and Scope of Practice	Record what happened, what changed, what the participant reported, what staff observed, what was measured, and why decisions were made.	The next clinician should be able to reconstruct the case without guessing.

Facilitator Competency Matrix: Know, Recognize, Support, Escalate

A facilitator does not need to become a cardiologist to work responsibly around ibogaine. They do need enough knowledge to recognize what is expected, notice when the course changes, support the person without making the situation worse, and activate the right clinical response without delay. The matrix below turns that boundary into observable practice.

Domain	Know	Support / do	Escalate when
Time course and phases	Acute effects, long inward/evaluative period, delayed recovery, sleep disruption, and variability across people	Protect time and space, avoid rushing the person, record actual timing rather than assuming a standard phase	The course changes abruptly, consciousness worsens, symptoms are prolonged beyond the expected trajectory, or the clinical picture no longer fits the known exposure.
Ataxia and mobility	Severe gait and coordination impairment can occur while awareness remains intact	Clear pathways, preplan toileting, use direct assistance, move slowly, keep needed items within reach, preserve dignity	Focal weakness, recurrent syncope, unexplained asymmetry, injury, worsening neurological findings, or mobility cannot be supported safely.
Vertigo and movement-sensitive nausea	Head and body movement may provoke nausea or disequilibrium in some participants	Keep unnecessary movement low, explain transitions, pause when symptoms rise, allow recumbent rest when appropriate, keep emesis supplies accessible	Persistent or atypical vertigo, severe headache, unusual nystagmus, syncope, altered consciousness, dehydration, or airway risk.
Vomiting and airway	Vomiting may be common, but aspiration, fluid loss, and electrolyte disturbance are medical concerns	Position safely, keep suction/emesis supplies accessible according to setting, notify clinical staff, track losses when relevant	Reduced airway protection, hypoxia, blood in emesis, persistent vomiting, progressive sedation, respiratory change, or significant dehydration.
Sensory environment	Light, sound, touch, alarms, staff traffic, and smell can become unusually intense	Use quiet, dimmable light, minimal traffic, participant-controlled music/ear protection when safe, avoid unnecessary scents and sudden changes	Sensory reduction interferes with monitoring or necessary assessment, or agitation/confusion suggests medical or psychiatric deterioration.
Communication and relational threat	The person may be deeply inward, frightened, confused, or temporarily perceive caregivers as threatening	Use one calm lead voice, short clear questions, explain actions before doing them, avoid arguing with content, avoid unnecessary staff conversations in the room, preserve choices where safe	Paranoia, agitation, delirium, mania, psychosis, unsafe behavior, or inability to complete necessary medical care.
Touch, privacy, and toileting	Ataxia can create dependence for intimate tasks without removing awareness or dignity	Discuss preferences before dosing, ask permission before non-emergency touch, use minimum necessary exposure, plan staff gender preference where relevant, protect privacy	Consent is unclear, the person resists nonessential touch, an emergency requires immediate intervention, or toileting/mobility becomes medically unsafe.
Hydration and food	Oral intake may be difficult during nausea/ataxia; food is supportive, not a substitute for medical correction	Offer small tolerated fluids or simple food only when swallowing and positioning are safe and consistent with the clinical plan; do not force intake	Persistent losses, aspiration concern, inability to swallow safely, significant electrolyte abnormality, renal/cardiac fluid concern, or altered consciousness.
Sleep and recovery	Wakefulness can persist and may complicate interpretation of mood and cognition	Protect rest, reduce stimulation, track sleep and activation, maintain continuity into the post-acute period	Escalating insomnia with mania, psychosis, delirium, suicidality, severe agitation, or functional deterioration.
Handoff and staff endurance	Sessions are long enough for fatigue to degrade judgment and relational steadiness	Use shifts, closed-loop handoff, shared records, clear unresolved-issue lists, and enough coverage that the primary attendant can eat, use the bathroom, and rest	The program cannot maintain safe observation, no qualified replacement is available, or fatigue is degrading monitoring and judgment.
Visionary intensity and grounding	Visual and autobiographical material can become overwhelming without being a medical emergency. Eye opening, orientation, and reduced sensory isolation may change intensity for some participants.	Use calm orientation, offer reversible grounding choices, reduce interpretive pressure, and preserve the participant’s choice to open the eyes or reduce immersion.	Distress is accompanied by delirium, dangerous behavior, severe agitation, loss of orientation, escalating mania or psychosis, or medically concerning change.
Transient persecutory mistrust	Acute threat interpretation may temporarily center on staff or monitoring. This overlaps with paranoid or persecutory ideation but is not automatically psychosis.	Use one calm lead voice, explain actions, reduce crowding and side conversations, preserve choices where safe, avoid confrontation, and document the participant’s actual words.	Mistrust becomes fixed or escalating, necessary care cannot be completed safely, threats or aggression emerge, consciousness changes, or mania, psychosis, delirium, withdrawal, hypoxia, or another medical cause is suspected.
Withdrawal and craving	Ibogaine may reduce withdrawal or craving signals, but dangerous alcohol or benzodiazepine withdrawal and ongoing OUD risk require ordinary addiction medicine.	Track symptoms, communicate changes, protect the prescriber owned plan, and do not treat subjective relief as proof that withdrawal or relapse risk has ended.	Seizure risk, delirium, uncontrolled autonomic instability, severe withdrawal, overdose risk, or a treatment plan cannot be safely maintained.
Cardiovascular symptom change	Palpitations, chest discomfort, presyncope, syncope, marked weakness, or monitor alarms can indicate clinically important change.	Stop nonessential activity, keep the participant safe, notify qualified clinical staff immediately, and document timing and symptoms without independently interpreting the ECG.	Syncope, sustained or recurrent arrhythmia, hemodynamic instability, chest pain with concerning features, hypoxia, or the setting exceeds its capability.
Respiratory change and aspiration risk	Sedative or opioid coexposure, vomiting, altered consciousness, and positioning can change airway risk.	Maintain safe positioning, keep airway and suction capability accessible according to setting, observe breathing, and summon clinical help early.	Reduced airway protection, hypoxia, progressive sedation, aspiration, abnormal breathing, or inability to maintain safe observation.
Post acute reentry	Residual ataxia, dizziness, sleep loss, medication changes, mood activation, and impaired judgment can continue after visions fade.	Restore independence gradually, reassess gait and function, review transport and supervision, support ordinary orientation, and complete handoff before discharge.	Unsafe mobility, unresolved cardiac findings, persistent vomiting, severe insomnia with activation, psychosis, suicidality, or the next setting cannot safely support the participant.

Field-practice convergence: the GITA guidelines, Lotsof/Wachtel manual, Wells provider notes, monitored clinical studies, and Rocha et al. clinical-trial guidance all converge on a practical reality that trials rarely quantify: a participant can become physically dependent for basic movement while remaining psychologically aware, and the quality of ordinary bedside support materially shapes both safety and the remembered experience.

In practice

Translate the knowledge requirements into a pre-session conversation between the people actually on shift. Ask who will recognize a change, who can make a clinical decision, and how help is summoned. A team member should be comfortable saying “I need the clinician to look at this.” Make those role boundaries understandable to the participant as well.

Expert practice · Project synthesis / non peer reviewed · Practice confidence: Expert Operational Practice

Dickinson (2016); Lotsof (2003); Wells · 2 more

View Evidence 6 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Historical and Cultural Orientation for Facilitators

Lotsof, traditional iboga contexts, contemporary practice, and limits of lineage or efficacy claims.

Ibogaine practice sits at the intersection of several histories. Tabernanthe iboga is a Central African plant embedded in living religious and healing traditions, including diverse Bwiti traditions in Gabon. Purified ibogaine hydrochloride in a medical facility shares an alkaloid lineage with iboga practice but is not the same intervention. A clinician or facilitator should be able to name that distinction without reducing traditional knowledge to decoration or presenting clinical pharmacology as the only legitimate way to understand the plant.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

Modern anti-addiction use developed through a separate twentieth century history that included Howard Lotsof, informal self-help networks, lay providers, medical clinics, activists, and research programs. Alper, Lotsof, and Kaplan described this as an ibogaine medical subculture with medical, lay, activist, and religious or spiritual settings, each carrying different assumptions and risk controls (Alper et al., 2008). That history explains why contemporary practice still contains procedures inherited from community experience alongside procedures derived from cardiology, addiction medicine, and clinical research.

Responsibility Level Tags

Not every safety obligation belongs to the person sitting closest to the participant. Public content and training tools should tag responsibilities by level so facilitators are not held responsible for system failures they cannot control.

Responsibility level	Typical responsibilities	Examples
FACILITATOR	Relational presence, participant preferences, movement support within role, environmental support, observation, communication, documentation, and prompt escalation.	Ataxia assistance, nausea triggers, sensory load, touch boundaries, handoff, reporting a change.
CLINICAL TEAM	Medical assessment, ECG and laboratory interpretation, medication decisions, withdrawal management, emergency treatment, consultation, and transfer decisions.	QT interpretation, electrolyte correction, seizure response, airway management, prescriber-owned medication plans.
PROGRAM / SYSTEM	Staffing redundancy, equipment readiness, emergency agreements, grievance independence, records, privacy, quality improvement, maintenance, backup power, and aftercare infrastructure.	Shift coverage, defibrillator maintenance, receiving-hospital pathway, incident review, provider disclosures, complaint escalation.

A professional facilitator should know which knowledge system a practice comes from. Traditional or ceremonial authority does not replace the medical chain of command during objective instability, and medical credentials do not create authority to represent Bwiti traditions. Where this lens touches cultural or ceremonial practice, provenance should remain visible and deeper cultural analysis should route to the separate Iboga Across Knowledge Systems lens.

Word of mouth from indigenous iboga practice describes offering banana when visions become too intense, with the intention of reducing the visions.

Related contemporary accounts describe a similar purpose. In an interview with Nick Urban, Jeff McNairy describes bananas being used to help people come down from the intensity of iboga (38:51). An online community account by Entheobirth describes retreats offering bananas after a session to temper lingering effects. These are practitioner and community accounts.

In practice

Ask what cultural, spiritual, or community meaning the participant brings to the experience. Describe the program’s own practices and limits clearly. When drawing on a tradition, identify the source and the people whose knowledge is being represented. Leave room for a participant to decline ritual or spiritual framing without compromising their access to respectful care.

Traditional / community practice · Project synthesis / non peer reviewed · Evidence gap

Alper (2008); Samorini (2025); Word of mouth from indigenous iboga practice: banana is offered with the intention of reducing visions when they become too intense. · 2 more

View Evidence 6 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Candidate Evaluation

Cardiac and neurological history, examination, withdrawal risk, testing, voluntariness, and the decision record.

Confirm that the screening record reflects the participant who is actually present today. Recheck meaningful changes in medical state, withdrawal, intoxication, medications, hydration, capacity, and support planning. Confirm preferences for communication, touch, sensory environment, toileting, and who may be present. If a medical question remains unresolved, route it to the person with the appropriate scope rather than treating facilitation readiness as medical clearance.

Current Practice Position

Responsibility: Facilitator · Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Established clinical risk · Project synthesis / non peer reviewed

Key sources: Knuijver (2022); Alper (2012); Rocha (2023) · 2 more View Evidence

Obtain and review a baseline 12 lead ECG before treatment. A history of syncope, known arrhythmia, structural heart disease, long QT, unexplained collapse, or sudden cardiac death in the family requires further cardiac assessment before elective administration.
Check potassium, magnesium, calcium, renal function, and hepatic function. Correct clinically significant electrolyte abnormalities before proceeding.
Postpone elective administration during active intoxication, uncontrolled alcohol or benzodiazepine withdrawal, acute medical illness, delirium, mania, psychosis, impaired consent capacity, or an unresolved cardiac abnormality.
Document the reason to proceed and the residual risk. The record should show what was identified, what was done about it, and who made the decision.

Building the Participant History and Clinical Context

Work from the person’s account toward a documented clinical picture. Keep questions open until the responsible person has resolved them.

Reason for seeking treatment
Start with the participant’s account. Ask what they hope will change, what they expect ibogaine to do, and what support they would use if the hoped for effect does not occur.
Clinical context and boundaries
Preparation begins with the first contact. Ask what the person expects ibogaine to do, what they believe will happen afterward, which decisions they are considering, and what supports they are willing to use if the treatment does not produce the hoped-for result. Correct claims of guaranteed detoxification, permanent abstinence, trauma cure, medical cure, or spiritual certainty before consent is signed.
Responsibility: Facilitator · Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Candidate Evaluation
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Current medical state
Reconstruct what has changed since the initial application. Separate the usual baseline from new symptoms, recent emergency care, illness, fluid losses, sleep, pain, fever, and current mobility.
Clinical context and boundaries
A person can be appropriate when accepted and unsafe when they arrive. Reconfirm the facts that can change between application and administration: current medications and supplements, last substance exposure, withdrawal trajectory, new illness or injury, vomiting or diarrhea, sleep deprivation, hydration, recent emergency care, and any medication started, stopped, or restarted. Reconfirm the emergency contact and the discharge or travel plan.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Arrival and Secondary Verification
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Cardiovascular history
Ask about episodes in their own words, then clarify circumstances, recurrence, prior evaluation, and available records. A label such as “fainting” is the beginning of the history.
Clinical context and boundaries
Cardiovascular history
Ibogaine and noribogaine can delay repolarization, and severe ventricular arrhythmias have been reported.
Ask specifically about syncope, palpitations, known arrhythmia, congenital long QT risk, structural disease, heart failure, conduction disease, ischemic history, implanted devices, and unexplained family sudden death. Abnormal history warrants clinician review and, where appropriate, cardiology input. Established clinical risk with ibogaine specific cases and general cardiology support.
Prior syncope or unexplained collapse
Syncope may be arrhythmic, neurological, orthostatic, or substance related.
Do not treat a remote label of “fainting” as self explanatory. Clarify circumstances, prodrome, exertional relationship, rhythm evaluation, medication context, and recurrence. Direct ibogaine evidence is limited; general cardiology relevance is strong.
Responsibility: Facilitator · Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Candidate Evaluation
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Neurological history
Establish what was present before treatment and what is new. Include seizures and withdrawal seizures, head injury, usual gait and coordination, weakness, tremor, and balance symptoms.
Clinical context and boundaries
Neurological and cerebellar
Orientation, speech, cranial findings when clinically indicated, tremor, coordination, gait, strength, focal deficit, preexisting vertigo or balance disorder.
Critical because ibogaine can produce severe transient ataxia and movement related symptoms.
Responsibility: Facilitator · Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Baseline Clinical Examination and Functional Reference · Related assessment and consent
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Medication reconciliation
Build one list that includes prescribed, nonprescribed, recently stopped, and restarted products. Ask explicitly about sleep aids, supplements, and medications used for withdrawal; identify the prescriber responsible for decisions.
Clinical context and boundaries
Reconcile every prescription, OTC product, supplement, nonprescribed medication, and recent recreational substance.
Flag QT prolonging agents, rate slowing or conduction active drugs, clinically important CYP2D6 inhibitors, sedatives, serotonergic agents, and medications that become dangerous if abruptly stopped.
Use a current QT medication resource such as CredibleMeds to support review, but let the responsible prescriber decide the medication plan.
Do not use a universal washout table. If a medication is stopped or changed, document the drug specific rationale, timing, active metabolites, organ function, discontinuation risk, and who is responsible for the decision.
Do not add a prophylactic antiemetic automatically. Several common antiemetics also affect QT or metabolism, so the antiemetic choice belongs inside the same interaction review.
Responsibility: Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Medication and Interaction Review
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Substance timeline
Put exposures in time order. For each substance, record amount where known, route, frequency, last use, tolerance, recent abstinence or relapse, current withdrawal, prior complications, and overdose history.
Clinical context and boundaries
The substance history needs a timeline. Record what was used, how much, the route, how often, the time of last use, current tolerance, expected withdrawal, previous withdrawal complications, overdose history, and anything being used to manage withdrawal. Polysubstance exposure deserves extra attention because opioids, benzodiazepines, alcohol, stimulants, and other agents appear repeatedly in severe cases and can change both physiology and interpretation.
Responsibility: Facilitator · Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Substance Use History
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Withdrawal trajectory
Connect last use, recent reductions, current symptoms, previous withdrawal complications, and the medications being used to manage withdrawal. Establish who owns stabilization and any transition plan before the treatment date is treated as settled.
Clinical context and boundaries
Opioids
Identify heroin, fentanyl and analog exposure, prescription opioids, methadone, buprenorphine, long acting products, last use, current tolerance, recent abstinence, overdose history and expected withdrawal.
Direct ibogaine studies often involve OUD, but protocols differ greatly. No universal transition or washout interval is validated across opioid types.
Alcohol
Assess current intake, last use, withdrawal history, delirium, seizure, nutrition and liver disease.
Alcohol withdrawal itself can be medically dangerous and can affect QT and electrolytes. Stabilization of dangerous withdrawal takes precedence over psychedelic treatment.
Benzodiazepines and other sedatives
Document prescribed and nonprescribed use, dependence, last dose, previous withdrawal seizure, respiratory depressant coexposures and current sedation.
Abrupt withdrawal can cause seizure and delirium. Sedative coexposure can also worsen respiratory and aspiration risk. Direct ibogaine interaction estimates are limited.
Recent abstinence or relapse
Establish how tolerance may have changed and whether current reported use matches the likely physiological state.
General addiction evidence shows overdose risk after tolerance loss. This is directly relevant to discharge planning even when acute ibogaine treatment appears successful.
Responsibility: Facilitator · Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Substance Use History
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Psychiatric and behavioral context
Begin with the current mental state, then reconstruct the course over time. Connect sleep, activation, medication changes, substance exposure, prior reactions, and the person’s usual function.
Clinical context and boundaries
Current mental status
Orientation, attention, thought process, perceptual disturbance, agitation, impulse control, mood, insight, judgment and ability to engage.
A baseline is necessary because acute ibogaine effects can later complicate interpretation.
Psychosis history
Prior psychotic episodes, attenuated symptoms, diagnosis, treatment response, current residual symptoms and substance related episodes.
Houenou et al. supports possible exacerbation in a vulnerable person, not a population level risk estimate.
Mania history and current activation
Prior episodes, decreased need for sleep, grandiosity, pressured speech, impulsivity, recent antidepressant or stimulant changes and family history.
Marta et al. reported three temporally associated manic syndromes. The series is a safety signal with important confounding, not proof of a universal contraindication.
Suicidality and homicidality
Current thoughts, intent, plan, recent behavior, protective factors, acute intoxication, agitation and access to appropriate emergency assessment.
Active high risk states require ordinary psychiatric emergency standards. Ibogaine does not substitute for crisis treatment.
Dissociation and cognitive impairment
Baseline depersonalization, derealization, memory problems, delirium risk, neurological disease and ability to understand the plan.
Important for capacity and for differentiating expected altered states from pathology.
Seizure and withdrawal history
Epilepsy, withdrawal seizures, head injury, current anticonvulsants, recent alcohol or benzodiazepine reduction.
Seizures are documented in toxicity reports, but predictors are poorly defined.
Prior difficult psychedelic reactions
Duration, behavioral consequences, emergency care, psychosis, mania, panic, self harm, or prolonged functional change.
Useful individualized history even though direct prediction evidence is limited.
Capacity
Ability to understand risks, alternatives, uncertainty, emergency authority and continuing care before intoxication begins.
Consent obtained after meaningful intoxication has begun cannot substitute for valid pre treatment consent.
Responsibility: Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Psychiatric and Neurobehavioral Evaluation
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Sleep trajectory
Reconstruct recent sleep alongside usual sleep, activation, substance use, and medication changes. Carry a change in sleep forward into the psychiatric assessment instead of leaving it as an isolated checkbox.
Clinical context and boundaries
Do not proceed with elective administration during active mania, psychosis, delirium, severe agitation, acute dangerousness to self or others, or impaired capacity to understand and consent.
A remote history of bipolar disorder, psychosis, dissociation, or a difficult psychedelic reaction should trigger a more detailed longitudinal assessment rather than an automatic decision.
Document recent sleep, medication adherence, stimulant and cannabis exposure, suicidality, impulsivity, baseline thought process, and the person’s usual level of functioning.
Arrange psychiatric consultation when current stability, diagnosis, medication changes, or the ability of the setting to manage deterioration is uncertain.
Responsibility: Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Psychiatric and Neurobehavioral Evaluation
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Previous difficult psychedelic reactions
Ask how long the reaction lasted, what happened behaviorally, whether emergency care was needed, and whether function changed afterward. Keep the account specific; the history supports individualized assessment without establishing a prediction.
Clinical context and boundaries
Prior difficult psychedelic reactions
Duration, behavioral consequences, emergency care, psychosis, mania, panic, self harm, or prolonged functional change.
Useful individualized history even though direct prediction evidence is limited.
Responsibility: Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Psychiatric and Neurobehavioral Evaluation
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Previous iboga or ibogaine exposure
Reconstruct each known episode rather than recording only “has used before.” Ask what preparation was used, in what setting, what happened during and afterward, and what records remain available.
Clinical context and boundaries
Prior iboga or ibogaine exposure
A previous uncomplicated exposure does not guarantee a future uncomplicated exposure; a previous adverse reaction may reveal vulnerability.
Document formulation, dose if known, product source, coexposures, duration, ECG or hospital findings, psychiatric effects, and delayed symptoms.
Responsibility: Facilitator · Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Candidate Evaluation
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Functional baseline
Record the person’s usual abilities and current support needs, including mobility, communication, cognition, and everyday activities. Distinguish participant report from examination findings.
Clinical context and boundaries
History identifies risk; examination establishes the reference point the team will need later. Document the parts of the physical and mental status examination that could become difficult to interpret once ibogaine is active. A baseline gait that is already unstable, preexisting tremor, dehydration, orthostasis, abnormal lung findings, or an irregular rhythm changes the meaning of the same finding several hours later.
Responsibility: Facilitator · Clinical team
Setting: Medically supervised administration · Research setting
Full lesson: Baseline Clinical Examination and Functional Reference
Evidence: Established clinical risk · Project synthesis / non peer reviewed · Sources and limitations
Social context
Ask about housing, interpersonal safety, substance exposure, and caregiving responsibilities. Identify which circumstances will still be present when the participant returns.
Clinical context and boundaries
Return environment
Housing stability, exposure to substances, interpersonal safety, stairs or mobility barriers, caregiving responsibilities, and whether someone can stay with the participant if needed.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Travel, Cross-Border, and Return-Environment Readiness
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Return environment
Walk through the practical return plan: where the person will stay, mobility barriers, medication access, and who can be present if support is needed. Record what is arranged and what remains a proposal.
Clinical context and boundaries
Return environment
Housing stability, exposure to substances, interpersonal safety, stairs or mobility barriers, caregiving responsibilities, and whether someone can stay with the participant if needed.
Medication continuity
Who restarts or changes medications, how prescriptions will be obtained, and which prescriber owns the plan.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Travel, Cross-Border, and Return-Environment Readiness
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Travel and transport
Establish who is accompanying the participant, the expected journey, and what happens if recovery is slower than planned. Carry forward emergency access and the medical summary needed during travel.
Clinical context and boundaries
Travel logistics
Who is accompanying the participant, how long travel takes, whether flights or long drives are planned, and what happens if recovery is slower than expected.
Emergency access
Local emergency number, receiving hospital, insurance or payment constraints, language access, and what medical summary travels with the participant.
Cross-border documentation
Passport and travel needs, lawful medication carriage, copies of relevant medical records, and treatment documentation appropriate to the jurisdiction.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Travel, Cross-Border, and Return-Environment Readiness
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Support network
Name the people and services who can actually be reached. Clarify addiction care, therapy, peer support, integration, and crisis contacts before discharge; identify gaps that still need an owner.
Clinical context and boundaries
Recovery support
Named contacts, addiction treatment, therapy, peer support, integration, and crisis contacts already arranged rather than suggested at discharge.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Travel, Cross-Border, and Return-Environment Readiness
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Records
List the records needed to resolve the history, including prior ECGs, laboratory results, and relevant hospital records. Compare dates and findings with the participant’s current state, and document missing information.
Clinical context and boundaries
Repeat testing when the previous result no longer represents the current state. GITA historically recommended a current ECG at intake and repeating older laboratory work when the clinical situation changed. This lens does not impose a universal expiration date on every test. The decision depends on the age of the result, intervening exposures, symptoms, medication changes, and the consequence of being wrong.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Arrival and Secondary Verification
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Collateral information
Clarify whom the participant permits the team to contact and what may be shared. Record the source of collateral information separately from the participant’s account and preserve unresolved differences.
Clinical context and boundaries
• Have privacy and confidentiality protected before, during, and after care, including preferences for how and when the program contacts them.
Responsibility: Program / system · Facilitator
Setting: Multiple settings
Full lesson: Participant Rights, Advocacy, Complaints, and Grievance · Related assessment and consent
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Unresolved questions
Keep a visible list of unanswered questions. For each, record the missing information, the next action, and who will follow it up. Completing a form does not resolve uncertainty.
Clinical context and boundaries
PRACTICE POSITION: a deferral should explain the reason in plain language, distinguish temporary from persistent concerns, document urgent risks, offer appropriate alternatives or referrals, and avoid shame. No person should be encouraged to hide medication use, substance exposure, or symptoms in order to “pass” screening.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Deferral, Reassessment, and Alternative Care Pathway
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Decision ownership
Name the owner of each next action: facilitator, clinical team, program, specialist, or participant. Keep medical authorization and medication decisions with the appropriate clinician. Use the responsibility matrix to resolve ambiguous ownership.
Clinical context and boundaries
Medical director or responsible physician
Owns medical eligibility criteria, unresolved medical risk, medication decisions, emergency medical policy, specialty consultation and transfer relationships.
Must be able to authorize postponement, additional evaluation, emergency escalation and transfer within the legal structure of the program.
Physician or advanced practice clinician
Performs medical assessment within scope, reviews ECG and relevant laboratory findings, evaluates symptoms, and initiates medical treatment when authorized.
Escalates outside expertise when the finding exceeds scope or facility capability.
Behavioral or psychological support
Provides orientation, reassurance, noncoercive support, observation of mental status and communication with the medical team.
Does not independently manage medical instability or exceed mental health licensure and program scope.
Pharmacy or medication support
Reviews interaction concerns, medication reconciliation, product handling and emergency medication readiness where available.
Escalates interaction and formulation concerns to the responsible prescriber.
Cardiology / toxicology consultation
Provides specialty interpretation for significant ECG, arrhythmia, toxicokinetic, interaction or poisoning questions.
Consultation should be available through a preplanned pathway when the program cannot resolve the issue internally.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Staffing and Scope of Practice
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations
Documentation
Pass forward the history, objective findings, unresolved issues, decisions, responsible people, and the reason for the decision. Keep the participant’s report distinct from observation and interpretation.
Clinical context and boundaries
Another qualified clinician should be able to pick up the record and understand the case. Document why the person was considered appropriate for the setting, which risks were identified, what was done about them, what product was given, how the person changed over time, and why major decisions were made. Keep patient report, clinician observation, objective findings, and interpretation visibly separate in the record.
Responsibility: Facilitator · Program / system
Setting: Multiple settings
Full lesson: Documentation Standard
Evidence: Expert practice · Project synthesis / non peer reviewed · Sources and limitations

Bring the findings together

Put recent substance use, medication changes, sleep, symptoms, and objective findings on the same timeline. Compare that timeline with the usual functional and mental state. The clinical record should show how the findings relate, which questions remain open, and who owns each decision.

What is established?: Separate the participant’s account, collateral information, observed behavior, and measured findings. Note when each was obtained.
What remains unresolved?: Name the missing record, examination, medication decision, consultation, or practical support. Keep the question open until the responsible person has addressed it.
What is the next action?: Record the decision, its rationale, who made it, and the next review or referral. Carry the same account into the handoff and explain the next step to the participant.

Documentation examples and evidence

Photorealistic illustration of an adult participant and clinician reviewing treatment paperwork, ECG information, and medications in a calm clinical room. — Editorial illustration
Image context
Illustrative editorial image: pre-treatment consultation and preparation. Not a clinical case photograph.

Before anyone gets ibogaine, the team needs a real picture of the person in front of them: cardiac history, medical conditions, neurological history, psychiatric course, current medications, and recent substance use. Screening works when unresolved findings stay unresolved long enough to be evaluated. A treatment date is easy to move; a missed risk is harder to undo.

Domain	Why it may matter	Evidence and practical implication
Cardiovascular history	Ibogaine and noribogaine can delay repolarization, and severe ventricular arrhythmias have been reported.	Ask specifically about syncope, palpitations, known arrhythmia, congenital long QT risk, structural disease, heart failure, conduction disease, ischemic history, implanted devices, and unexplained family sudden death. Abnormal history warrants clinician review and, where appropriate, cardiology input. Established clinical risk with ibogaine specific cases and general cardiology support.
Prior syncope or unexplained collapse	Syncope may be arrhythmic, neurological, orthostatic, or substance related.	Do not treat a remote label of “fainting” as self explanatory. Clarify circumstances, prodrome, exertional relationship, rhythm evaluation, medication context, and recurrence. Direct ibogaine evidence is limited; general cardiology relevance is strong.
Seizure and neurological history	Convulsions have been reported in toxicity cases, and severe ataxia is documented in monitored cohorts.	Clarify epilepsy, withdrawal seizures, head injury, neurological disease, previous unexplained convulsions, and current antiseizure therapy. A history does not automatically establish an ibogaine specific contraindication, but it can materially change the need for specialist assessment and setting capability.
Hepatic disease	Ibogaine undergoes extensive hepatic metabolism, and serious liver disease appeared in fatality reports.	Assess clinically meaningful hepatic disease and medication burden. Severe liver disease may alter exposure and competing cardiac risk, but the literature does not provide a validated hepatic function cutoff for ibogaine.
Renal disease	Renal dysfunction may alter electrolyte handling and the management of complications.	Renal function is commonly screened in clinical research. Direct evidence linking a specific renal threshold to ibogaine outcomes is inadequate.
Electrolyte disturbance	Hypokalemia and hypomagnesemia are established general modifiers of acquired TdP risk and have appeared in ibogaine fatality and toxicity reports.	A known or suspected electrolyte abnormality should be evaluated and clinically corrected before exposure. No ibogaine specific potassium or magnesium target has been validated.
Pregnancy	Pregnancy changes physiology and fetal risk and is commonly excluded from early phase studies.	The available human ibogaine pregnancy evidence is inadequate for safety characterization. Pregnancy therefore represents an evidence gap requiring specialist and jurisdiction specific decision making rather than an invented risk estimate.
Acute medical illness	Fever, dehydration, infection, vomiting, poor intake, and hemodynamic instability can change physiological reserve and electrolyte status.	Eligibility on paper is not the same as same day readiness. Acute illness should trigger reassessment and may justify postponement until the cause and trajectory are understood.
Prior iboga or ibogaine exposure	A previous uncomplicated exposure does not guarantee a future uncomplicated exposure; a previous adverse reaction may reveal vulnerability.	Document formulation, dose if known, product source, coexposures, duration, ECG or hospital findings, psychiatric effects, and delayed symptoms.
Prior psychedelic or anesthetic adverse events	Past reactions may expose vulnerabilities in airway, hemodynamic, emergence, agitation, delirium, or psychiatric response.	Direct ibogaine prediction data are limited. Use the history to guide differential assessment, not to create unsupported categorical exclusions.

Voluntariness, Motivation, and Expectation Setting

Ibogaine should not be framed as something a family, employer, court, partner, or provider can make work by coercing the participant. Historical provider guidance repeatedly treated willingness and realistic expectations as part of readiness, and contemporary ethics supports voluntary informed participation. Motivation is clinically relevant, but there is no validated motivation score that predicts ibogaine outcome. The practical task is to establish that the person understands what is being proposed, wants to participate, can ask questions and refuse, and is not being sold a guaranteed cure.

Preparation begins with the first contact. Ask what the person expects ibogaine to do, what they believe will happen afterward, which decisions they are considering, and what supports they are willing to use if the treatment does not produce the hoped-for result. Correct claims of guaranteed detoxification, permanent abstinence, trauma cure, medical cure, or spiritual certainty before consent is signed.

In practice

Make disclosure easier by explaining why each part of the history is being asked. A participant may fear that honesty will cost them access to care. Respond without humiliation, clarify uncertainty, and document the concern accurately. End the assessment with a shared account of the next step, including who will follow up on outstanding questions.

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); Alper (2012); Rocha (2023) · 2 more

View Evidence 6 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Preparation as Participant Skill Building

A reflective baseline, coping inventory, grounding preferences, uncertainty, and return environment planning.

Preparation can also be used to build practical self-observation before the participant is altered. The useful goal is not to script the experience in advance. It is to help the person understand the physiological and safety context, notice how they respond to stress and loss of control, identify grounding and coping methods they already trust, and make the return environment less chaotic. These practices can improve communication and participant agency even when they do not predict what the ibogaine experience will contain.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

Participant journaling in a calm home setting as part of preparation and readiness. — Editorial illustration
Image context
Illustrative editorial image: preparation and readiness before treatment. Not clinical documentation.

Preparation element: Use in this lens
Physiology-first education: Explain what the substance may do to the body, why monitoring is used, and which symptoms should be reported. Avoid promising a specific visionary, emotional, or spiritual sequence.
Reflective snapshot: Optional journaling or notes can capture current concerns, goals, habits, sleep, relationships, stressors, and questions before treatment. Treat the record as participant-owned reflection unless the person chooses to share it; it is not a diagnostic test.
Coping inventory: Ask what already helps when the person is anxious, overwhelmed, nauseated, physically uncomfortable, or uncertain. Identify familiar breathing, grounding, attentional, sensory, or body-awareness practices and what has not helped in the past.
Control and uncertainty: Discuss how the person typically responds when control is reduced, expectations are not met, or an experience becomes difficult to interpret. Preparation should increase flexibility without requiring surrender to any specific belief system.
Habits and return environment: Identify routines, relationships, obligations, home stressors, and practical changes that could support recovery after treatment. Environmental preparation is a support strategy, not a moral test or eligibility gate.
Body familiarity and grounding preferences: Participant-selected movement, body awareness, tapping, grounding, or similar practices may be rehearsed as familiar self-regulation options. Present them as optional supports, not proven ibogaine interventions.
Program and setting literacy: Teach participants to compare medical, clinical, community, and ceremonial settings by actual capability, role clarity, emergency access, consent practices, lineage claims, and fit with the participant's values. The categories can coexist without being treated as interchangeable.
Meaning-work boundaries: Optional reflection on imagery, archetypes, 'shadow' material, forgiveness, or spirituality belongs to the participant. Do not require a therapeutic narrative, force forgiveness, or present a facilitator's interpretation as the correct meaning.

PROJECT AUTHOR PREPARATION NOTES / NON PEER REVIEWED: This section incorporates operational preparation ideas from Nicolas' 2023 presentation notes. The notes are used for participant reflection, communication, grounding preferences, return-environment planning, and program literacy. Specific medication, psychiatric, diet, supplement, tapping, bodywork, archetypal, or other intervention claims are not promoted as ibogaine-specific clinical evidence.

In practice

Practice one or two usable skills with the participant before the session: asking for a pause, describing a bodily sensation, or naming a preferred form of reassurance. Ask what has helped during previous distress and what has made it worse. Record these preferences in the handoff so they do not disappear when another facilitator takes over.

Expert practice · Project synthesis / non peer reviewed · Practice confidence: Expert Operational Practice

Nicolas (2023); Dickinson (2016)

View Evidence 3 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Participant Rights, Advocacy, Complaints, and Grievance

Privacy, intimate care, access to records, advocacy, grievances, and practical accountability.

Explain rights before intoxication, keep optional consent separate, know the grievance pathway, and do not interpret refusal as resistance. If the complaint involves the primary provider, the participant needs another route for escalation.

Responsibility: Program / system · Facilitator
Applies in: Multiple settings

Community ibogaine practice developed explicit patient-rights language because altered-state vulnerability, medical risk, and uneven provider regulation create a real power imbalance. The GITA version of the Ibogaine Patient’s Bill of Rights is not statutory law, but several of its protections are useful operational standards: the person should know what form of ibogaine they are receiving, who is responsible for care and what credentials they hold, what alternatives exist, what risks and limitations are known, and how to refuse optional interventions. Privacy, access to records, a complaint pathway, and freedom from unnecessary restraint should be built into the program rather than treated as courtesy.

Right / expectation: What it looks like in practice
Information: Explain product/formulation, treatment plan, known risks, uncertainty, alternatives, provider roles, and emergency pathway before intoxication.
Choice: Optional music, touch, spiritual framing, bodywork, family contact, and other non-emergency practices remain voluntary.
Privacy and dignity: Plan bathroom and clothing assistance in advance; minimize exposure, explain what is happening, and do not turn dependence created by ataxia into humiliation.
Refusal: A competent participant can refuse non-emergency interventions. Medical emergencies and loss of capacity require the pre-agreed clinical chain of command.
Records and accountability: Document care sufficiently for the participant and future clinicians to reconstruct what occurred; provide a visible complaint or error-reporting route.

Participant rights

Information about your care

Know the name, role, qualifications, relevant experience, and scope of the people responsible for care.
Receive understandable information about the proposed intervention, major uncertainties, foreseeable risks, alternatives, and what emergency escalation would look like.

Choice and questions

Refuse nonemergency touch, ritual, music, disclosure, interpretation, adjunctive practices, photography, research participation, or other optional elements.
Ask questions and receive clarification without being treated as resistant or uncommitted.

Privacy and records

Have privacy and confidentiality protected before, during, and after care, including preferences for how and when the program contacts them.
Review or receive appropriate treatment records according to applicable law and program policy.

Complaints and accountability

Provide negative feedback, report an incident, or file a grievance without retaliation.
Know who receives complaints and how concerns can be escalated when the complaint involves the primary provider.

Communication assistance

Receive language or communication assistance when needed for meaningful consent and safety.

Leaving treatment

Leave treatment when legally capable of doing so, with a documented risk discussion and safer alternatives rather than unlawful detention.

What Competent Care Should Look Like From the Participant Side

A participant should be able to recognize the basic features of competent care before arriving. This is not a clinic-rating system. It is a transparency checklist that makes expectations visible before the person is intoxicated or physically dependent on staff.

Participant should be able to answer: Minimum transparency expected
Who is responsible for my medical care?: Name, role, licensure or scope where applicable, and who owns emergency medical decisions.
Who will actually be with me during treatment?: Expected staffing, overnight coverage, handoff structure, and who can enter the room.
What is optional?: Clear boundaries around touch, music, ritual, bodywork, photography, research, testimonials, visitors, and disclosure.
What happens if treatment is delayed or cancelled?: Reason for deferral, what can be corrected, alternative care, referral, and conditions for reassessment.
What happens if I want to leave?: Capacity assessment, unresolved risks, safer alternatives, transportation, emergency instructions, and documentation rather than coercion.
How are emergencies handled?: Monitoring capability, onsite response, EMS activation, receiving facility, and how clinical information travels with the participant.
How do I report a concern?: A grievance route that does not depend only on the person being complained about and protection from retaliation.
What happens after treatment?: Discharge criteria, medication plan, overdose prevention, follow-up, continuing addiction care, records, and who owns unresolved questions.

In practice

Make the complaint pathway understandable before the participant depends on staff for intimate or medical care. Explain how they can ask for another staff member or an independent conversation. Receive a concern without requiring the person to prove it is justified while distressed, and ensure it reaches the appropriate responsible person.

Expert practice · Project synthesis / non peer reviewed · Practice confidence: Expert Operational Practice

Ibogaine Patient’s Bill of Rights. Reproduced in Clinical Guidelines for Ibogaine-Assisted Detoxification (GITA; Dickinson (2016); Karpetas (2010)

View Evidence 4 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Provider Transparency Profile

Qualifications, clinical coverage, monitoring capability, conflicts of interest, and optional services.

State role and limits plainly. Personal recovery or ibogaine experience can be valuable, but it does not replace medical, nursing, mental-health, or emergency competence that the role requires.

Responsibility: Program / system · Facilitator
Applies in: Multiple settings

Participant view should show the questions a person is entitled to ask any program, including programs with no relationship to this project. A provider should be able to disclose credentials and scope accurately, relevant ibogaine experience, medical responsibility, ownership or referral relationships, conflicts of interest, emergency partners, aftercare arrangements, and the limits of what the program can safely manage.

PROGRAM / SYSTEM RESPONSIBILITY: provider disclosure, grievance independence, record access, conflict disclosure, emergency agreements, and quality review are organizational duties. They should not be shifted onto the bedside facilitator.

Separate Optional Consent From Treatment Consent

Consent to receive care does not automatically authorize research, publication, photography, audio or video recording, testimonials, marketing use, sharing with donors, or release of identifiable clinical material. Where these activities exist, use separate optional consent. Refusal should not reduce access to care. If data will be used for research or quality improvement, tell the participant what is collected, who can access it, how it is de-identified, how long it is retained, and whether withdrawal of permission is possible after data have been aggregated or published.

Karpetas’ 2010 ethics framework also emphasized disclosure of financial interests and incentives. The contemporary version is straightforward: disclose referral fees, ownership relationships, sponsorships, research conflicts, or other financial interests that could reasonably influence the recommendation a participant receives.

In practice

Describe actual roles, supervision, and response capability using concrete examples. A participant should be able to tell who is a facilitator, who provides nursing or medical care, and who makes decisions when concerns arise. Keep experience claims and professional credentials specific and verifiable.

Expert practice · Project synthesis / non peer reviewed · Practice confidence: Expert Operational Practice

Dickinson (2016); Karpetas (2010)

View Evidence 3 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Clinical assessment and readiness

Evaluate the cardiovascular, neurological, psychiatric, medication, nutritional, and withdrawal picture before administration.

Editorial illustration

Image context

Illustrative editorial image: preparation and readiness before treatment. Not clinical documentation.

Baseline Clinical Examination and Functional Reference

Establish cardiovascular, airway, neurological, hydration, withdrawal, and mental status reference findings.

History identifies risk; examination establishes the reference point the team will need later. Document the parts of the physical and mental status examination that could become difficult to interpret once ibogaine is active. A baseline gait that is already unstable, preexisting tremor, dehydration, orthostasis, abnormal lung findings, or an irregular rhythm changes the meaning of the same finding several hours later.

Responsibility: Facilitator · Clinical team
Applies in: Medically supervised administration · Research setting

The examination should remain problem focused rather than ritualized. Cardiovascular, pulmonary, neurological, hydration, withdrawal, intoxication, and mental status findings deserve enough detail to support the actual risk picture. A person with a stable chronic finding may still be appropriate for a setting that can evaluate it; an unexplained new finding should stay unresolved until somebody with the right scope has resolved it.

Domain	Baseline focus	Why it matters later
Cardiovascular	Rate and rhythm, blood pressure, orthostatic symptoms when relevant, perfusion, signs of heart failure or active cardiopulmonary disease when suspected.	Provides context for later bradycardia, hypotension, syncope, chest symptoms, or rhythm change.
Pulmonary and airway	Work of breathing, oxygenation when indicated, airway risk, abnormal lung findings, current respiratory infection or aspiration concern.	Helps separate later sedation, aspiration, opioid coexposure, or respiratory deterioration from baseline.
Neurological and cerebellar	Orientation, speech, cranial findings when clinically indicated, tremor, coordination, gait, strength, focal deficit, preexisting vertigo or balance disorder.	Critical because ibogaine can produce severe transient ataxia and movement related symptoms.
Hydration and nutrition	Recent intake, vomiting/diarrhea, mucous membranes, orthostatic symptoms, body weight and clinically relevant signs of malnutrition.	Changes electrolyte risk, drug tolerance, mobility, and post treatment recovery.
Withdrawal and intoxication	Objective signs appropriate to the substance history, sedation, agitation, autonomic activation and consistency with reported last use.	Helps detect unstable withdrawal or unreported recent exposure.
Mental status and function	Attention, orientation, thought process, mood, behavior, sleep trajectory, judgment, capacity, ability to follow safety instructions and usual level of function.	Provides the reference needed to distinguish an altered experience from delirium, mania, psychosis, or deterioration.

Standardized measures should be used when they add longitudinal value. COWS or another validated opioid withdrawal measure, an appropriate alcohol withdrawal instrument when alcohol withdrawal is clinically relevant, SARA when formal ataxia tracking is useful, and structured mental status or delirium tools can improve trend interpretation. Do not add scales simply to make the record look objective.

In practice

Establish a baseline through an ordinary interaction as well as a checklist. Learn how this person normally speaks, walks, responds, and asks for help. Account for disability, language, hearing, vision, and usual communication style so that later differences are interpreted in relation to the individual rather than staff assumptions.

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); Alper (2012); Rocha (2023) · 1 more

View Evidence 5 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Arrival and Secondary Verification

Reconcile intervening exposures, symptoms, medications, test relevance, and discharge arrangements.

Reconcile the current state with the pre-treatment file and route any discrepancy that could change risk to the responsible clinician. A negative screening test does not replace a complete history or knowledge of the assay’s limits.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

A person can be appropriate when accepted and unsafe when they arrive. Reconfirm the facts that can change between application and administration: current medications and supplements, last substance exposure, withdrawal trajectory, new illness or injury, vomiting or diarrhea, sleep deprivation, hydration, recent emergency care, and any medication started, stopped, or restarted. Reconfirm the emergency contact and the discharge or travel plan.

Repeat testing when the previous result no longer represents the current state. GITA historically recommended a current ECG at intake and repeating older laboratory work when the clinical situation changed. This lens does not impose a universal expiration date on every test. The decision depends on the age of the result, intervening exposures, symptoms, medication changes, and the consequence of being wrong.

Toxicology testing can verify selected recent exposures but must be interpreted with the limitations of the local assay in mind. A negative screening panel does not prove that every clinically relevant substance is absent. Ask directly, reconcile the history, and order analyte-specific or confirmatory testing when the answer could change care. Handling of personal medications or substances should be transparent, respectful, documented, and proportionate to actual safety needs rather than conducted as a punitive search.

In practice

Receive the person before beginning the verification tasks. Allow a private opportunity to report a change since screening, and make clear that the team needs accurate information. Travel fatigue, disrupted meals, and a difficult journey can also affect what practical support is needed while the clinical review is completed.

Expert practice · Project synthesis / non peer reviewed · Practice confidence: Expert Operational Practice

Dickinson (2016); I.ACT Aotearoa/New Zealand. (2014)

View Evidence 3 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Substance Use History

Last use, tolerance, polysubstance exposure, withdrawal history, and substance specific assessment.

The substance history needs a timeline. Record what was used, how much, the route, how often, the time of last use, current tolerance, expected withdrawal, previous withdrawal complications, overdose history, and anything being used to manage withdrawal. Polysubstance exposure deserves extra attention because opioids, benzodiazepines, alcohol, stimulants, and other agents appear repeatedly in severe cases and can change both physiology and interpretation.

Current Practice Position

Responsibility: Facilitator · Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Established clinical risk · Project synthesis / non peer reviewed

Key sources: Alper (2012); Mazoyer (2013); Malcolm (2018) · 2 more View Evidence

Build an exact substance timeline for the previous days and weeks, including fentanyl, methadone, buprenorphine, long acting opioids, alcohol, benzodiazepines, stimulants, sedatives, and any nonprescribed medications.
Alcohol and benzodiazepine dependence should be medically stabilized before ibogaine. Do not create a withdrawal seizure or delirium problem in order to reach an ibogaine date.
For OUD, use a prescriber led transition plan rather than an informal washout. Methadone and other QT active agents add cardiac complexity, while abrupt opioid changes add withdrawal and relapse risk.
Before discharge, reassess tolerance loss and overdose risk. The person should leave with naloxone access and a clear plan for what happens if craving or opioid use returns.

Substance domain	Specific questions	Evidence boundary
Opioids	Identify heroin, fentanyl and analog exposure, prescription opioids, methadone, buprenorphine, long acting products, last use, current tolerance, recent abstinence, overdose history and expected withdrawal.	Direct ibogaine studies often involve OUD, but protocols differ greatly. No universal transition or washout interval is validated across opioid types.
Methadone	Record dose, timing, duration, QT history, other QT prolonging agents, and the intended plan for maintenance or transition.	Methadone has independent QT liability and long, variable kinetics. Some ibogaine protocols transitioned participants to shorter acting opioids, but those study procedures should not be presented as universal practice.
Buprenorphine	Record dose, formulation, last use, current withdrawal and treatment goals.	Ibogaine specific evidence on transition from buprenorphine remains limited. Do not invent an abstinence interval.
Alcohol	Assess current intake, last use, withdrawal history, delirium, seizure, nutrition and liver disease.	Alcohol withdrawal itself can be medically dangerous and can affect QT and electrolytes. Stabilization of dangerous withdrawal takes precedence over psychedelic treatment.
Benzodiazepines and other sedatives	Document prescribed and nonprescribed use, dependence, last dose, previous withdrawal seizure, respiratory depressant coexposures and current sedation.	Abrupt withdrawal can cause seizure and delirium. Sedative coexposure can also worsen respiratory and aspiration risk. Direct ibogaine interaction estimates are limited.
Stimulants	Assess recent cocaine, methamphetamine, prescription stimulant or novel stimulant exposure, chest pain, sleep deprivation, agitation and cardiovascular symptoms.	Stimulant exposure may add autonomic and cardiac stress. Quantitative ibogaine interaction risk is not established.
Cannabis and novel psychoactive substances	Record regular use and recent exposure rather than assuming benignity.	These substances can complicate mental status, anxiety, psychosis risk and toxicology interpretation. Direct interaction evidence is sparse.
Recent abstinence or relapse	Establish how tolerance may have changed and whether current reported use matches the likely physiological state.	General addiction evidence shows overdose risk after tolerance loss. This is directly relevant to discharge planning even when acute ibogaine treatment appears successful.

Alcohol Use Disorder: New Direct Human Data

A 2026 open label pilot adds direct human data in moderate to severe alcohol use disorder. Nine adults received ibogaine hydrochloride under hospitalization and continuous monitoring. QTc changes occurred in five participants, mild or moderate blood pressure changes were observed, and nausea, drowsiness, and anxiety were common. Two participants required medication for psychomotor agitation, insomnia, and hypertension. No serious adverse events were reported, but the sample was too small to estimate rare-event risk (Rocha et al., 2026). This study strengthens the case for treating alcohol related nutritional status, withdrawal, blood pressure, sleep, agitation, and cardiac monitoring as one integrated safety problem rather than importing an opioid detoxification protocol unchanged.

In practice

Use concrete, nonjudgmental questions about substances, amounts, timing, route, and recent changes. Explain that the purpose is to understand interactions, intoxication, withdrawal, and continuity of treatment. If a history is incomplete, document what is uncertain and involve the clinician instead of treating disclosure as a test of character.

Established clinical risk · Project synthesis / non peer reviewed

Alper (2012); Mazoyer (2013); Malcolm (2018) · 2 more

View Evidence 6 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Medication and Interaction Review

Explore QT effects, bradycardia, CYP2D6, sedation, withdrawal, and prescriber owned transitions.

Verify medication reconciliation rather than assuming someone else completed it. Ask about common omissions, recent antibiotics, antihistamines, sleep aids, psychiatric medications, methadone, buprenorphine, benzodiazepines, stimulants, supplements, and recently discontinued agents. Do not create a washout plan outside scope. Route medication decisions to the prescriber and preserve the reason, timing, and source behind the final plan.

Current Practice Position

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Established clinical risk · Project synthesis / non peer reviewed

Key sources: Knuijver (2022); Knuijver (2024); Hildyard (2016) · 5 more View Evidence

Reconcile every prescription, OTC product, supplement, nonprescribed medication, and recent recreational substance.
Flag QT prolonging agents, rate slowing or conduction active drugs, clinically important CYP2D6 inhibitors, sedatives, serotonergic agents, and medications that become dangerous if abruptly stopped.
Use a current QT medication resource such as CredibleMeds to support review, but let the responsible prescriber decide the medication plan.
Do not use a universal washout table. If a medication is stopped or changed, document the drug specific rationale, timing, active metabolites, organ function, discontinuation risk, and who is responsible for the decision.
Do not add a prophylactic antiemetic automatically. Several common antiemetics also affect QT or metabolism, so the antiemetic choice belongs inside the same interaction review.

In practice

Give the participant one clear, prescriber-owned plan they can refer to. Clarify responsibility for medication changes before arrival and after discharge, including who to contact if symptoms develop. Reconcile what the person actually took with what the written plan intended; a misunderstanding may be more useful to identify than a label of nonadherence.

Clinical Detail

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); Knuijver (2024); Hildyard (2016) · 5 more

View Evidence 9 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Cardiovascular Evaluation

ECG acquisition, QT measurement, correction, morphology, temporal instability, and current practice markers.

Explain monitoring in plain language so the participant understands why leads, serial ECGs, and observation continue even when they feel well. Facilitators do not independently interpret QT or arrhythmias, but they should recognize symptoms, monitor alarms, syncope, new weakness, or abrupt change and bring them to clinical staff immediately. Preserve calm while medical staff evaluate the tracing and trajectory.

Current Practice Position

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Established clinical risk · Project synthesis / non peer reviewed

Key sources: Knuijver (2022); Knuijver (2024); Hildyard (2016) · 8 more View Evidence

Obtain a resting 12 lead ECG and document rate, rhythm, PR, QRS, measured QT, QTc, correction method, T wave morphology, U waves when relevant, ectopy, and comparison with prior ECGs when available.
Manually verify any ECG with a concerning automated QTc, abnormal T wave termination, marked bradycardia, ectopy, or a value near a decision threshold. Use the same measurement method and correction formula for serial comparison whenever possible.
Knuijver et al. excluded participants with QTc above 450 ms in men or 470 ms in women. Treat those values as a research protocol benchmark rather than a validated universal ibogaine cutoff. A value at or above that range represents unresolved cardiac risk that deserves qualified review before elective exposure, and a value below it does not establish safety.
During treatment, QTc above 500 ms or a rise of at least 60 ms from baseline should trigger immediate reassessment, correction of reversible factors, intensified monitoring, and cardiology or toxicology input.
New ventricular ectopy, couplets, T wave alternans, pause dependent short long short sequences, syncope, or polymorphic ventricular rhythm increases concern even before a single QTc value tells the whole story.

In practice

Introduce monitoring equipment before the participant is deeply altered. Explain what an ECG records, who interprets it, and why repeat checks may occur even when the person feels well. Invite questions about wires, alarms, privacy, or movement, and plan how monitoring can continue with the least avoidable discomfort.

Clinical Detail

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); Knuijver (2024); Hildyard (2016) · 8 more

View Evidence 12 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Cardiac Risk Modifiers

Bradycardia, electrolytes, medications, underlying disease, withdrawal, and interacting risks.

Arrhythmia risk appears to emerge from the combination of baseline vulnerability, exposure, and physiological stress. Several modifiers are established in acquired long QT medicine and recur in ibogaine cases, including electrolyte disturbance, bradycardia, interacting drugs, structural disease, and metabolic differences. Their exact ibogaine specific effect sizes remain unknown.

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting

In practice

Review the combined picture in the team discussion. A participant should not have to navigate several disconnected explanations about medications, vomiting, electrolytes, or previous fainting. Assign responsibility for each unresolved issue and give one coherent account of how it affects the current plan.

Clinical Detail

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); Alper (2012); Rocha (2023) · 4 more

View Evidence 8 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Laboratory Evaluation

Potassium, magnesium, calcium, renal and hepatic findings, repeat testing, and threshold provenance.

Know which laboratory issues are part of the participant’s risk picture and which decisions belong to clinicians. Do not present food, electrolyte drinks, supplements, or community practices as medical replacement for measured abnormalities. If vomiting, diarrhea, poor intake, medication changes, or new illness develop, recognize that previously acceptable values may no longer describe the current state.

Current Practice Position

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Established clinical risk · Project synthesis / non peer reviewed

Key sources: Knuijver (2022); Alper (2012); Rocha (2023) · 1 more View Evidence

Before administration, confirm potassium, magnesium, and calcium are within the laboratory reference range and correct clinically meaningful abnormalities.
Check renal and hepatic function because organ dysfunction can change electrolyte handling, drug exposure, medication options, and emergency management.
Use pregnancy testing when pregnancy is possible and the result would change the plan.
Use toxicology testing when the substance timeline is uncertain, the result changes management, or the clinical state does not match the history. Do not use a negative screen to overrule a plausible exposure the assay does not detect.

In practice

Explain the purpose of sampling and any repeat testing. If a result changes the plan, tell the participant what is being addressed and how it will be reassessed. Use the measured result and the responsible clinician’s plan rather than inviting the participant to correct a suspected deficiency independently.

Clinical Detail

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); Alper (2012); Rocha (2023) · 1 more

View Evidence 5 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Physiological Readiness

Reassess hydration, intake, withdrawal, sleep, vital signs, and current capacity before administration.

A person can look appropriate at screening and arrive on dosing day dehydrated, sleep deprived, intoxicated, withdrawing, febrile, vomiting, sedated, orthostatic, or cognitively different from baseline. That changes the decision. Reassess the current state before administration; earlier eligibility only describes the earlier visit.

Readiness domain: Questions before proceeding
Hydration and intake: Has the person been able to drink and eat? Is there recent vomiting or diarrhea? Are orthostatic symptoms, dry mucosa, low urine output, or another sign suggesting clinically important volume loss?
Withdrawal: Is the person entering an expected withdrawal trajectory or an unstable one? Is there risk of alcohol or benzodiazepine withdrawal seizure or delirium? Are objective findings consistent with the reported last use?
Intoxication and sedation: Is mental status sufficiently clear for reliable reassessment and consent? Is there ongoing opioid, sedative, alcohol, stimulant, or novel substance intoxication?
Sleep and physiological stress: Has prolonged sleep loss, agitation, exertion, pain, or other stress materially changed the person’s condition?
Mobility and baseline neurology: Can the person ambulate safely before administration? Is there preexisting ataxia, weakness, tremor, focal deficit, or confusion that would make later changes difficult to interpret?
Acute illness: Is there fever, infection, chest pain, dyspnea, unexplained tachycardia, gastrointestinal illness, or another active medical problem that should be evaluated first?

Practice note: a formal readiness score is unnecessary when the physiological change is obvious. Document the finding, what was done to evaluate or correct it, and the reasoning behind the same day decision.

In practice

Revisit readiness as a conversation and a clinical assessment on the planned day. Ask how the person has slept, eaten, felt, and managed prescribed instructions. Acknowledge the pressure to proceed after travel or expense, while keeping the decision grounded in the current assessment.

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); O’Connell (2015); Mazoyer (2013)

View Evidence 4 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Nutrition, Hydration, Bowel Function, and Micronutrient Support

Bowel preparation, swallowing safety, thiamine, magnesium, targeted repletion, and nutrition across the stay.

Build nutrition into preparation, bedside support, and discharge. Ask what the person usually eats, what they can afford and tolerate, and whether recent substance use, withdrawal, nausea, dental problems, or restrictive eating has disrupted intake. Coordinate a feasible plan with the clinical team; general healthy eating advice must be adapted to the person’s actual condition.

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting

Before arrival, clarify food access, preferences, allergies, usual intake, bowel function, and any concerning weight or intake change. Arrange clinician or dietitian input where needed. Provide explicit instructions for food and fluid timing around administration; do not leave participants to infer a fasting rule from a wellness diet.

During recovery, confirm alertness and swallowing safety before oral intake, offer tolerable portions without pressure, document intake and losses, and escalate persistent vomiting or poor intake. At discharge, discuss who will obtain or prepare food and whether the person can manage it independently. The plan should be workable at home as well as in the treatment room.

The practical goal is to bring the participant into treatment with enough physiological reserve to tolerate a long session and enough bowel, bladder, hydration, and nutritional stability that basic care does not become a preventable crisis. Aggressive cleanses, unnecessary fasting, diarrhea inducing preparations, or indiscriminate fluid loading can create the electrolyte and volume problems the team is trying to avoid.

Ibogaine commonly reduces appetite during the acute experience, and severe ataxia can make ordinary eating, drinking, and toileting difficult. Plan hydration and nutrition across the entire episode rather than trying to correct everything immediately before dosing. Oral intake should be guided by alertness, nausea, aspiration risk, and the ability to swallow safely. Clinically significant electrolyte abnormalities require laboratory guided medical correction, not food based approximation.

Bowel function also matters because constipation can become much harder to manage once the person is ataxic and unwilling or unable to walk. Community ibogaine guidance has historically emphasized adequate bowel movements and avoiding aggressive bowel preparations that cause diarrhea or electrolyte loss. That is expert and community practice rather than validated trial evidence, but the operational concern is legitimate: constipation, diarrhea, and repeated bathroom trips all become harder when gait is severely impaired.

Ginger and Other Simple Comfort Measures

Ginger appears repeatedly in historical and community ibogaine practice as tea or another simple oral support for nausea. General clinical literature outside ibogaine also supports anti-nausea effects of ginger in several settings, although the evidence quality and effective preparations vary (Li et al., 2024). No ibogaine trial has established ginger as a treatment for ibogaine-induced nausea, and it should not be used to delay evaluation of persistent vomiting, aspiration risk, dehydration, withdrawal, or an abnormal cardiac or neurological picture.

If the participant wants it, swallowing is safe, and the medical plan allows oral intake, small amounts of ginger tea or another familiar non-irritating preparation can be treated as a comfort measure. The same principle applies to small sips of tolerated fluid, cool cloths, a change in room temperature, or a requested adjustment in light or sound. The intervention should solve the problem the participant actually has without creating a new one.

SUPPORTIVE PRACTICE: Ginger is a general anti-nausea option with external evidence and longstanding field use, not an ibogaine-specific antiemetic protocol.

Clinical Detail

Established clinical risk · Project synthesis / non peer reviewed

Alexander H. Flannery (2016); Maguire (2022); Cherian (2024) · 7 more

View Evidence 11 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Psychiatric and Neurobehavioral Evaluation

Mood and psychosis history, suicidality, cognition, capacity, sleep, and differential assessment.

Psychiatric screening should start with the person’s current state and the history that tells you how stable that state has been. Mania, psychosis, prolonged insomnia, and confusion have all been reported after ibogaine. Active mania, psychosis, delirium, dangerous agitation, severe suicidality, or impaired capacity call for stabilization before elective treatment. A remote diagnosis needs a more careful longitudinal look at course, medications, substance context, support, and, when appropriate, psychiatric consultation.

Current Practice Position

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Established clinical risk · Project synthesis / non peer reviewed

Key sources: Marta (2015); Houenou (2011); Ona (2022) View Evidence

Do not proceed with elective administration during active mania, psychosis, delirium, severe agitation, acute dangerousness to self or others, or impaired capacity to understand and consent.
A remote history of bipolar disorder, psychosis, dissociation, or a difficult psychedelic reaction should trigger a more detailed longitudinal assessment rather than an automatic decision.
Document recent sleep, medication adherence, stimulant and cannabis exposure, suicidality, impulsivity, baseline thought process, and the person’s usual level of functioning.
Arrange psychiatric consultation when current stability, diagnosis, medication changes, or the ability of the setting to manage deterioration is uncertain.

In practice

Ask how the person experiences stress, loss of sleep, unusual perceptions, or changes in mood, and what previous support has been helpful. Distinguish their usual beliefs and communication from a recent change in functioning. Arrange appropriate clinical evaluation without debating or imposing an interpretation of personal meaning.

Clinical Detail

Established clinical risk · Project synthesis / non peer reviewed

Marta (2015); Houenou (2011); Ona (2022)

View Evidence 4 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Travel, Cross-Border, and Return-Environment Readiness

Cross border logistics, transport, receiving care, accompaniment, costs, and destination readiness.

Treat transport, housing, support, medication continuity, overdose prevention, mobility, and emergency access as discharge variables. A clinically stable person can still be unsafe in the destination environment.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

Many people travel long distances or cross borders for ibogaine. Screening should therefore include the environment the person is leaving and the environment they will return to. A medically stable discharge can still fail if the participant has no safe transport, no reachable support, no plan for medications, no naloxone where opioid relapse is possible, or a home environment that immediately recreates the conditions that drove treatment.

Domain: Questions to resolve before treatment
Travel logistics: Who is accompanying the participant, how long travel takes, whether flights or long drives are planned, and what happens if recovery is slower than expected.
Emergency access: Local emergency number, receiving hospital, insurance or payment constraints, language access, and what medical summary travels with the participant.
Return environment: Housing stability, exposure to substances, interpersonal safety, stairs or mobility barriers, caregiving responsibilities, and whether someone can stay with the participant if needed.
Medication continuity: Who restarts or changes medications, how prescriptions will be obtained, and which prescriber owns the plan.
Recovery support: Named contacts, addiction treatment, therapy, peer support, integration, and crisis contacts already arranged rather than suggested at discharge.
Cross-border documentation: Passport and travel needs, lawful medication carriage, copies of relevant medical records, and treatment documentation appropriate to the jurisdiction.

Historical GITA guidance recommended travel medical coverage for people crossing borders. The exact insurance product is jurisdiction-dependent, but the underlying practice point remains useful: do not discover after an emergency that the participant cannot access or pay for the intended level of care.

In practice

Build the return plan with the person who will use it. Confirm practical details such as accompaniment, access to food, medication support, and follow up in the home region. Identify which arrangements can be changed if observation runs longer, and avoid making discharge depend on a flight or a hotel checkout.

Expert practice · Project synthesis / non peer reviewed · Practice confidence: Expert Operational Practice

Dickinson (2016); I.ACT Aotearoa/New Zealand. (2014)

View Evidence 3 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Special Populations

Assess population specific concerns and distinguish direct evidence from unstudied extrapolation.

The evidence is still too small for a long list of population specific protocols. Keep separate guidance only where the literature identifies a clinically meaningful concern. In many groups, the most accurate answer is that risk is plausible, more evaluation may be warranted, and the field has not yet established an ibogaine specific rule.

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting

In practice

Begin with the individual’s functional needs, preferences, and existing care rather than assumptions based on a category. Ask what accommodations have worked previously and involve appropriate expertise early. Be explicit about where direct evidence is limited and whether the setting has the capability required.

Clinical Detail

Established clinical risk · Project synthesis / non peer reviewed

Alper (2012); Papadodima (2013); Knuijver (2022) · 2 more

View Evidence 6 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Pharmacology, formulation, and evidence

Interpret exposure, metabolism, formulation, and published outcomes in their clinical and study context.

Editorial illustration

Image context

Illustrative educational image. The product, batch, purity, chromatogram, dates, QR code, and analytical values shown are synthetic examples and do not represent an actual tested product. Ibogaine HCl is shown in its typical white crystalline powder form. Not a dosing guide.

Supportive and Emergency Medications

Medication readiness, torsades treatment, seizure rescue, antiemetic choices, and toxicity response.

Prepare medications for the complications the team may need to treat: torsades, unstable bradycardia, seizures, repeated vomiting, withdrawal, and severe agitation or toxicity. Established cardiology, resuscitation, neurology, and toxicology guidance provides the clinical foundation. Applying those standards during ibogaine care requires attention to the person’s ECG, electrolytes, breathing, coexposures, and current level of consciousness.

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting

The reference below connects recognized treatments to ibogaine’s risk profile. General emergency standards apply to the emergency being treated; ibogaine case reports add context about prolonged toxicity and recurrence. Choices drawn from postoperative antiemetic research are identified as extrapolations. The clinical lead should turn these references into written orders with doses, routes, repeat limits, monitoring, and transfer triggers before administration.

Medications and equipment to have ready

Clinical need	Medication readiness	Required capability
Torsades and electrolyte loss	Injectable magnesium sulfate; a protocol for potassium replacement.	Defibrillator, continuous ECG, IV access, infusion pump, electrolyte testing, and emergency transfer.
Unstable bradycardia	Atropine; access to the protocol’s epinephrine or dopamine infusion.	Pacing capability, blood pressure monitoring, trained resuscitation staff.
Prolonged seizure	A rapidly deliverable benzodiazepine, such as IV lorazepam or IM midazolam.	Oxygen, suction, assisted ventilation, glucose testing, and a second treatment pathway.
Persistent vomiting	An antiemetic selected in advance for the person’s QT, interaction, and sedation risks; isotonic IV fluid when indicated.	Airway assessment, intake and loss records, repeat electrolytes, and reassessment after treatment.
Withdrawal or severe agitation	Indication specific benzodiazepine orders; thiamine when indicated by alcohol or nutritional history.	Repeated neurological and respiratory assessment, withdrawal expertise, and escalation capacity.
Refractory toxicity	A receiving service able to provide pacing, advanced airway care, and continuous infusions.	Confirm actual availability and transfer arrangements; these treatments need hospital level capability.

Readiness check: verify the exact product, concentration, expiry, storage conditions, access permissions, dilution instructions, and stock needed for repeat treatment. Assign a clinician to medication decisions and another team member to record administration times and response. Include the facility’s broader emergency stock, including anaphylaxis, opioid overdose, and hypoglycemia treatment, in its resuscitation checklist. This stock organization is an operational synthesis for medically supervised care.

Clinical sources

Part 9: Advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care · DOI: 10.1161/CIR.0000000000001376
Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society · DOI: 10.5698/1535-7597-16.1.48
Pharmacological treatment of acquired QT prolongation and torsades de pointes · DOI: 10.1111/bcp.12726

Torsades and prolonged QT

Sustained polymorphic VT requires immediate unsynchronized defibrillation. Start CPR if there is no pulse. Recurrent torsades with prolonged QT calls for magnesium and correction of precipitants, including potassium depletion. Stop contributing QT prolonging agents. Pacing or isoproterenol may be needed when pauses or bradycardia sustain recurrences. These are established emergency interventions (Wigginton et al., 2025).

Treatment	Adult reference and clinical purpose	Monitoring and limits
Magnesium sulfate	For recurrent torsades with a pulse, Thomas and Behr describe 2 g IV over 10 to 15 minutes; further treatment depends on recurrence and reassessment.	Follow the resuscitation protocol for arrest. Monitor ECG, blood pressure, respiration, renal function, and magnesium. A normal serum magnesium does not exclude benefit in torsades.
Potassium replacement	Correct hypokalemia; acquired long QT guidance commonly targets the high normal range.	Use measured values, renal function, a controlled infusion, and repeat testing. Never give potassium by IV push.
Rate support	Expert directed isoproterenol or temporary pacing for recurrent acquired, pause dependent torsades despite initial treatment.	Requires continuous monitoring. Isoproterenol may worsen ischemia or some congenital long QT syndromes.
Antiarrhythmic selection	Identify whether polymorphic VT occurs with a prolonged QT.	Amiodarone, sotalol, and procainamide can add repolarization delay. Do not carry a normal QT ventricular arrhythmia drug sequence into acquired long QT torsades without specialist assessment.

Ibogaine reports describe prolonged and recurrent arrhythmias requiring intensive care, including temporary pacing. Initial rhythm recovery therefore needs continued monitoring and a transfer plan (Hildyard et al., 2016; Henstra et al., 2017).

Clinical sources

Part 9: Advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care · DOI: 10.1161/CIR.0000000000001376
Pharmacological treatment of acquired QT prolongation and torsades de pointes · DOI: 10.1111/bcp.12726
A case of QT prolongation and torsades de pointes caused by ibogaine toxicity · DOI: 10.1016/j.jemermed.2015.06.051
Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine · DOI: 10.1080/15563650.2017.1287372

Bradycardia and perfusion

Treat bradycardia according to perfusion: hypotension, shock, ischemic discomfort, acute heart failure, or altered consciousness change the response. Atropine is an initial option. If ineffective, transcutaneous pacing or an epinephrine or dopamine infusion can support the patient while definitive care is arranged. Confirm both electrical and mechanical capture during pacing. A slow rate combined with prolonged QT and pauses also needs the torsades pathway (Wigginton et al., 2025).

Clinical sources

Part 9: Advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care · DOI: 10.1161/CIR.0000000000001376

Seizures and GABA mediated treatment

Benzodiazepines enhance GABA mediated inhibition and are established initial treatment for drug related seizures. A convulsion lasting five minutes, or repeated seizures without recovery, requires the status epilepticus pathway. Time the seizure, protect the airway, check glucose, and obtain emergency help while treating (Glauser et al., 2016; Chen et al., 2016).

Medication	Adult emergency reference	Bedside requirements
Lorazepam IV	AES guidance uses 0.1 mg/kg, maximum 4 mg per dose; it may be repeated once for persistent convulsions under the protocol.	Give at the protocol’s controlled IV rate. Track cumulative doses, breathing, oxygenation, blood pressure, and seizure cessation.
Midazolam IM	AES guidance uses 10 mg IM in patients over 40 kg when IV access is unavailable.	Keep oxygen, suction, and assisted ventilation immediately available. This is a seizure treatment dose, not a routine anxiety dose.
Further treatment	Persistent seizures need rapid escalation to an IV antiseizure drug or anesthetic treatment appropriate to the cause.	Toxicology and neurology should guide selection. Refractory cases need airway and intensive care capability.

The cause matters after benzodiazepines. Levetiracetam, fosphenytoin, and valproate had similar overall effectiveness in the ESETT trial of established status epilepticus (Kapur et al., 2019). Toxicological seizures need additional reasoning: Chen et al. advise against phenytoin for drug induced seizures and describe barbiturates or propofol when benzodiazepines fail. Propofol belongs in care with airway control and cardiovascular support. These pathways should be settled with the receiving service before an event.

Clinical sources

Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society · DOI: 10.5698/1535-7597-16.1.48
Treatment of drug-induced seizures · DOI: 10.1111/bcp.12720
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus · DOI: 10.1056/NEJMoa1905795

Persistent vomiting and antiemetic selection

Repeated vomiting can deplete potassium and magnesium while making oral medication unreliable. Assess consciousness, airway protection, hydration, abdominal symptoms, and recent medication exposure; check the ECG and electrolytes when losses persist. Use an appropriate nonoral route when needed. Correct fluid and electrolyte losses alongside symptom treatment. In ibogaine care, choosing among antiemetics requires extrapolation from their known pharmacology and evidence in other populations.

Agent or class	What the evidence contributes	Implication during ibogaine care
Ondansetron; droperidol	Both produced QTc prolongation in postoperative patients in Charbit et al. (2005).	Review current QT, bradycardia, electrolytes, and other QT active drugs. Repeated dosing or combining QT active agents needs explicit justification and monitoring.
Palonosetron	A controlled study found no significant QTc effect in healthy volunteers (Morganroth et al., 2016).	A potential option when minimizing QT burden. Its QT findings do not establish safety in an ibogaine exposed patient; review the full clinical and interaction picture.
Aprepitant / fosaprepitant	A controlled healthy volunteer study found no significant QTc effect (2009).	An NK1 antagonist option for clinician review. Check CYP mediated interactions, formulation, timing, and whether evidence supports the intended prevention or rescue use.
Dexamethasone	No QTc prolonging effect is described in the perioperative review; its principal role there is prevention.	It is not a rapid rescue choice for ongoing hyperemesis. Consider glucose, infection, and psychiatric effects when selecting a prevention strategy.
Scopolamine	A vestibular antiemetic option without a described QT effect in the perioperative review.	A patch has a delayed onset. Anticholinergic confusion, visual disturbance, and urinary effects may complicate an altered state.
Metoclopramide; promethazine; haloperidol	The perioperative review describes QT concerns; sedation or extrapyramidal effects vary by drug.	Check repolarization and neurological risks before use. A different receptor target does not automatically resolve the interaction problem.

A 5-HT3 antagonist blocks a serotonin receptor. It should not be described as simply increasing serotonin. Product warnings about serotonin toxicity with combinations exist, but the causal interpretation is disputed in the pharmacology literature (Rojas-Fernandez, 2014). QT risk remains a separate, documented consideration. Assess the actual combination, examination, and trajectory rather than treating the word “serotonergic” as a diagnosis.

Clinical sources

Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron · DOI: 10.1097/00000542-200506000-00006
Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers · DOI: 10.1007/s00520-015-2822-6
Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects · DOI: 10.1213/ane.0b013e3181ac1066
PONV management in patients with QTc prolongation on the EKG · DOI: 10.3389/fphar.2020.565704
Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order · DOI: 10.1007/s40801-014-0004-3

Serotonin toxicity, agitation, and withdrawal

After a serotonergic exposure, clonus, hyperreflexia, agitation, sweating, rising temperature, or rigidity should prompt assessment for serotonin toxicity. Vomiting alone does not establish it. Stop implicated agents, use benzodiazepines for agitation and muscle activity when indicated, and provide fluids and active cooling. Severe hyperthermia or rigidity requires urgent airway control, paralysis, and intensive care. Cyproheptadine may be considered with toxicology input; it is an oral adjunct with uncertain outcome benefit, so stabilization must continue while that decision is made (Chiew & Isbister, 2025).

For alcohol withdrawal, benzodiazepines are first line treatment; thiamine and nutritional assessment belong in the plan. Phenobarbital requires experienced clinicians and appropriate monitoring. Clonidine or dexmedetomidine can reduce autonomic symptoms but do not replace treatment that prevents withdrawal seizures and delirium. Their effects on rate and blood pressure matter in someone already prone to bradycardia. A person entering significant alcohol or benzodiazepine withdrawal needs medical withdrawal care (ASAM, 2020).

For severe agitation, first establish whether the driver is withdrawal, hypoxia, delirium, serotonin toxicity, pain, or a psychiatric syndrome. Sedation can reduce observable distress while impairing ventilation or obscuring neurological deterioration. Antipsychotic selection needs attention to QT and the diagnostic context. Give the participant a brief explanation when possible, maintain a familiar voice, and reassess after every intervention.

Clinical sources

Management of serotonin syndrome (toxicity) · DOI: 10.1111/bcp.16152
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management · DOI: 10.1097/ADM.0000000000000668

Orders, reassessment, and handoff

Order or record	Required detail	Reason
Before treatment	Indication, product and concentration, route, dose, repeat interval, maximum, monitoring, and prescriber.	A responder should not have to invent a regimen during deterioration.
After each intervention	Time, dose, rhythm, blood pressure, respiratory status, mental state, and symptom response.	Distinguishes improvement from adverse effects or continuing toxicity.
Escalation	Who calls EMS, who manages the airway and monitor, who contacts the receiving clinician.	Treatment and transfer can proceed together.
Handoff	Ibogaine product and timing, coexposures, ECGs, laboratory results, treatments, and response.	The receiving team needs the exposure and intervention timeline.

In practice

At the pre treatment briefing, walk through the actual emergency medication kit with the clinical lead. Know who can prescribe and administer each drug, who will continue direct participant support, and when transfer begins. Explain during preparation that treatment may include medication, fluid replacement, a shock, breathing support, or hospital care according to the problem. In an emergency, tell the person what is happening in a calm, brief sentence while the team acts.

Established clinical risk · Project synthesis / non peer reviewed

Knuijver (2022); Alper (2012); Rocha (2023) · 16 more

View Evidence 20 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Safety Relevant Pharmacology and Pharmacokinetics

Ibogaine and noribogaine time course, CYP2D6 variability, formulation, and delayed effects.

Pharmacokinetic and phenomenological timeline

The same nominal dose can produce very different exposure from one person to the next. CYP2D6 is a major reason. Reduced activity or pharmacologic inhibition can drive parent ibogaine concentrations much higher, and the 2024 OUD pharmacokinetic study linked CYP2D6 activity to clearance and ibogaine concentration to QTc change. Noribogaine then carries the pharmacology forward for much longer. The number on the label is only one part of the exposure story.

Current Practice Position

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Mechanistic evidence · Emerging evidence · Project synthesis / non peer reviewed

Key sources: Glue (2015); Glue (2015); Glue (2016) · 3 more View Evidence

Treat CYP2D6 activity as a real exposure modifier. The strongest human PK data show more than tenfold variability in ibogaine clearance across CYP2D6 activity scores.
CYP2D6 genotype or phenotype testing can be considered in an elective medical protocol when a qualified clinician can interpret the result, but routine testing has not been shown prospectively to improve clinical outcomes or support a validated dose adjustment algorithm. Treat the result as one exposure modifier, not a stand-alone dosing calculator.
Strong CYP2D6 inhibition should trigger a deliberate prescriber and pharmacy review before treatment rather than being treated as a minor interaction.
Do not assume that a common commercial flood dose is a demonstrated safe dose. A monitored 10 mg/kg study already produced clinically substantial QTc changes.

In practice

Use the time course to plan staffing and observation, and explain it without making a prediction about this individual. The participant’s subjective experience and the measured clinical trajectory may move at different speeds. Handoffs should carry both forward rather than treating a quieter room as proof that the physiological work is finished.

Clinical Detail

Mechanistic evidence · Emerging evidence · Project synthesis / non peer reviewed

Glue (2015); Glue (2015); Glue (2016) · 3 more

View Evidence 7 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Observed Human Exposure and Dose Context

Compare reported exposure, populations, monitored outcomes, and limits of translating study protocols.

This section is not a dosing guide. It places published human exposures beside the population, formulation, and observed effects so the reader can see why a single “safe dose” cannot be extracted from the literature. Exposure depends on formulation, body size, metabolism, CYP2D6 inhibition, coexposures, product identity, and the clinical condition of the person receiving it.

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting

In practice

When discussing a published study, keep its formulation, population, monitoring, and setting attached to the result. Ask whether the participant has heard a dose claim from another program and clarify what can and cannot be inferred. A study description should help explain evidence, not become an informal prescribing instruction.

Clinical Detail

Emerging evidence · Project synthesis / non peer reviewed

Alper (2000); Alper (2012); Alper (2016) · 24 more

View Evidence 28 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Practice Landscape, Not Dosing Guidance: Flood, Split, Extended, and Repeat-Dose Models

Flood, split, extended, and repeat models: provenance, practical variation, and evidence limits.

Know whether the program uses a single-session, split, extended/cumulative, or repeat-dose model. Do not present provider preference as comparative proof of safety or efficacy, and do not import dosing rules from another model without a full medical and pharmacologic review.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

DESCRIPTIVE PRACTICE LANDSCAPE. This section exists so practitioners can recognize the model operating around them. It does not recommend a dose, cumulative exposure, redosing interval, or preferred treatment model. No comparative trial has established that one real-world dosing model is globally safer or more effective.

Real-world ibogaine practice is not organized around one dosing model. Historical manuals, contemporary providers, and Enginsoy’s qualitative interviews describe single-session “flood” approaches, split administration, extended or cumulative administration over a longer period, and later booster or maintenance use. Formulations also vary. This section describes the landscape because facilitators need to recognize what model they are working inside. It is not a dosing guide.

Practice model	Description	Source of knowledge	Evidence boundary
Single-session / flood model	A large proportion of the intended exposure is given in one treatment episode, often with an intense oneirogenic period.	Most historical detox literature and many published treatment descriptions use this model.	Direct human safety data remain limited; high-intensity exposure, ataxia, QT effects and prolonged recovery require medical monitoring.
Split dosing within one episode	Exposure is divided across more than one administration during a treatment episode.	Appears in provider protocols and clinical practice.	No comparative evidence establishes a universally safer or more effective split strategy.
Extended / cumulative model	Smaller repeated administrations are used over days or longer, sometimes while other treatment changes occur.	Documented in contemporary provider reports and Enginsoy’s interviews; publicly described by Pangea Biomedics.	Provider claims of improved tolerability or safety are hypotheses and experience reports, not comparative proof.
Booster / tune-up / maintenance use	Additional ibogaine is used after an initial treatment for recurrence, psychological work, or maintenance.	Described historically by Kroupa and Wells and other provider sources.	Evidence for long-term benefit, optimal timing, cumulative cardiac risk and interaction with recovery care is inadequate.
Traditional iboga patterns	Iboga root bark or other preparations may be used within traditional or ceremonial contexts that do not map cleanly onto Western dosing categories.	Traditional knowledge and ethnographic sources.	Do not translate ceremonial practice into an ibogaine-HCl dosing protocol.

FIELD PRACTICE POSITION: no comparative trial has established that one real-world dosing model is globally safer or more effective. Programs should state which model they use, why, what evidence supports it, what uncertainties remain, and how monitoring and staffing match the exposure pattern. Participant-facing material should describe the model without giving a self-administration recipe.

NAMED CONTEMPORARY PROVIDER COMMENTARY: Jonathan Dickinson of Ambio describes an integration principle that “more is not necessarily better,” emphasizing a post-treatment process that makes use of the opened period rather than reflexively repeating exposure. This is retained as provider philosophy and expectation-setting commentary, not comparative dosing evidence or a redosing rule.

In practice

Explain the program’s administration model in terms the participant can understand, including how decisions are made and how monitoring follows the plan. Invite questions about uncertainty or differences between programs. Keep discussion descriptive and direct patient-specific decisions to the responsible clinician.

Expert practice · Evidence gap · Project synthesis / non peer reviewed

Enginsoy (2025); Kroupa (2005); Pangea Biomedics. (2026) · 1 more

View Evidence 5 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Product Identity and Formulation

Identity, formulation, analysis, batch, storage, exposure reconstruction, and ethical traceability.

Write down exactly what the person is receiving. Purified ibogaine hydrochloride, total alkaloid extract, root bark, and an internet capsule cannot be treated as interchangeable exposures. The current practice position favors an analytically verified, batch traceable preparation with enough documentation to reconstruct what was given if the clinical picture changes.

Current Practice Position

Responsibility: Facilitator · Clinical team
Applies in: Medically supervised administration · Research setting
Evidence basis: Established clinical risk · Project synthesis / non peer reviewed

Key sources: O’Connell (2015); Mazoyer (2013); Kontrimavičiūtė (2006) · 1 more View Evidence

For a medical protocol, use a batch traceable, analytically verified preparation with documented identity, concentration, purity, storage, and expiry or stability information.
Record body weight, calculation method, total amount administered, exact time, and every additional administration.
Do not convert root bark, total alkaloid extract, or an unknown capsule into an assumed ibogaine HCl equivalent unless a validated analytical result supports that conversion.
Retain enough product and lot information to investigate an adverse event later.

Illustrative educational image showing iboga root bark, extract, purified ibogaine HCl in white crystalline powder form, and analytical testing documents to emphasize source, composition, testing, and traceability. — Editorial illustration
Image context
Illustrative educational image. The product, batch, purity, chromatogram, dates, QR code, and analytical values shown are synthetic examples and do not represent an actual tested product. Ibogaine HCl is shown in its typical white crystalline powder form. Not a dosing guide.

Product field	What to record	Reason
Formulation	Ibogaine HCl, whole plant material, total alkaloid extract, other defined product, or unknown product.	Different formulations cannot be assumed to deliver the same alkaloid profile or dose.
Source and batch	Manufacturer or supplier, lot, batch, date obtained, storage history and chain of custody where applicable.	Allows later product investigation and links events to a traceable batch.
Analytical verification	Certificate of analysis, method, measured ibogaine content, other known alkaloids, purity and contaminants.	O’Connell and Mazoyer demonstrate that measured content can materially improve interpretation of exposure.
Dose documentation	Body weight when a weight based method is used, calculation method, amount administered, time of each administration, redosing and concurrent agents.	Allows reconstruction of the actual clinical course without endorsing a particular dose.
Unknown constituents	Record when the product is not analytically characterized.	Dose and causal inference should be explicitly qualified when product composition is uncertain.

Ethical Traceability and Provenance

Product history matters beyond analytical purity. When the supply chain is known, distinguish material extracted from Tabernanthe iboga, semisynthetic ibogaine made from voacangine or another precursor, and fully synthetic material. Record what is actually known about provenance, sustainability, authorization, and benefit sharing alongside the analytical data.

CURRENT PRACTICE POSITION FROM QUALITY AND ETHICAL PRACTICE: document product source and manufacturing route when known, keep certificates and analytical results, and describe lineage or traditional authorization only when the program actually holds it. For plant derived material, record what is known about lawful sourcing, provenance, and sustainability. These are ethical and quality considerations and should be kept separate from validated predictors of cardiac risk.

In practice

Show how the team records product identity and traceability and explain why that information travels with the clinical record. Avoid treating a polished certificate or marketing term as sufficient reassurance. Document what has actually been verified and make unresolved product questions part of the decision before administration.

Established clinical risk · Project synthesis / non peer reviewed

O’Connell (2015); Mazoyer (2013); Kontrimavičiūtė (2006) · 1 more

View Evidence 5 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Cardiac Mechanism

hERG blockade, reduced repolarization reserve, active metabolite effects, and limits of mechanistic inference.

The best supported mechanism for ibogaine related QT risk is hERG blockade. hERG carries IKr, a major outward potassium current involved in ventricular repolarization. When IKr is reduced, the action potential lengthens and susceptibility to early afterdepolarizations and polymorphic ventricular arrhythmia can rise in the right physiological setting. Alper et al. measured low micromolar hERG blockade from both ibogaine and noribogaine, so the metabolite remains part of the cardiac picture.

Responsibility: Clinical team
Applies in: Medically supervised administration · Research setting

In practice

Use the mechanism to explain the reason for precautions, without asking the participant to master electrophysiology. A short explanation that electrical recovery can be delayed may be enough for consent and cooperation. Keep mechanistic teaching distinct from the clinician’s interpretation of the actual tracing and the person’s condition.

Clinical Detail

Mechanistic evidence · Emerging evidence · Project synthesis / non peer reviewed

Alper (2016); Litjens (2016)

View Evidence 3 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Traditional and Community Knowledge

Lineage, preparation, knowledge permissions, reciprocity, and responsible cultural attribution.

Ibogaine comes from a living Central African knowledge system, not from Western clinical medicine. Tabernanthe iboga is tied to ceremony, community, ecology, and governance. Purified ibogaine HCl in a medical facility shares a molecule with traditional iboga practice, but it is a different intervention and should be described that way.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

This lens keeps traditional and community practice as its own source of knowledge. It can surface questions formal research has missed, teach us about setting and relational containment, and preserve knowledge held by experienced practitioners and communities. Use each source for the kind of claim it can actually support: medical thresholds, event rates, and contraindications need the evidence appropriate to those claims, while living cultural knowledge remains valuable even when it never entered PubMed.

Domain: Responsible treatment in this lens
Lineage and representation: State accurately whether a practice comes from clinical medicine, community ibogaine practice, or a named traditional lineage. Do not imply initiation, authorization, or indigenous endorsement that is not actually present.
Ceremonial elements: Use only when they are appropriate to the participant and within the competence or authorization of the people offering them. Participation should remain voluntary.
Knowledge attribution: Credit traditional or community knowledge as such rather than converting it into a Western clinical claim without evidence.
Sourcing and ecology: Where plant derived material is used, consider provenance, sustainability, conservation pressure, lawful sourcing, and benefit sharing in addition to purity and potency.
Collaboration: When research or programming draws materially on traditional practice, direct engagement with knowledgeable and authorized community representatives is preferable to symbolic borrowing.
Clinical authority: Traditional or ceremonial authority does not replace the medical chain of command when a participant develops objective medical instability.

In practice

Name the community, person, or text when the provenance is known and say when it is not. Ask how the knowledge is intended to be used and what permission or cultural review may be needed. Preserve distinctions between ceremonial meaning, operational experience, and claims about physiological effects.

Traditional / community practice · Project synthesis / non peer reviewed

Samorini (2025); Alper (2008)

View Evidence 3 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Evidence Gaps

Explore 24 unresolved questions, the available findings, and the studies needed to address them.

Several of the biggest evidence gaps sit exactly where clinicians want firm answers: washout, dose selection, monitoring duration, discharge thresholds, and individual risk prediction. The current literature is strong enough to build a serious risk management system and still too thin for false precision.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

Unresolved research questions

Search unresolved research questions

Entry

Unresolved question	What is known	What is still needed
Optimal monitoring duration	Monitored studies use different windows. QT abnormalities can persist beyond 24 hours, and severe toxicity cases document several days of abnormality.	Prospective studies linking concentration, ECG trajectory and clinical events to a validated stopping rule.
Best QT correction method in ibogaine treatment	Fridericia has been used in clinical studies. General ECG data show formula performance changes with heart rate. Bradycardia is common with ibogaine.	Prospective comparison of correction approaches in ibogaine with standardized ECG acquisition and concentration effect analysis.
Clinical role of noribogaine	Noribogaine persists longer than ibogaine and has hERG activity. Severe toxicokinetic cases show delayed metabolite exposure alongside prolonged QT abnormality.	Larger concentration ECG studies establishing how much noribogaine independently contributes to clinical arrhythmia risk.
Dose and arrhythmia risk	QT change and severe events occur across reported exposures, and dose estimates are often uncertain.	Standardized pharmaceutical product studies across doses with adequate sample size and concentration data.
CYP2D6 and meaningful clinical risk	CYP2D6 strongly influences parent ibogaine exposure. Inhibition with paroxetine substantially changes PK.	Validated clinical strategy showing whether genotype or phenotype testing improves outcomes and how results should change treatment.
Medication interactions	Mechanistic concerns are clear for QT active, rate slowing and CYP interacting drugs.	Prospective drug interaction studies and evidence based medication management intervals.
Washout periods	Different studies and programs have used different transition procedures.	Drug specific, indication specific intervals based on kinetics, withdrawal risk and outcome data. No universal ibogaine washout schedule exists.
Electrolyte strategy	General TdP prevention supports correction of potassium and magnesium abnormalities. Ibogaine cases include electrolyte disturbances.	Ibogaine specific target ranges and prospective evidence that a particular supplementation strategy changes outcomes.
Product variability	Analytically confirmed cases show that product content can differ from assumptions. Whole plant and extracts contain multiple alkaloids.	Routine standards for identity, purity, alkaloid profile, contaminants, stability and chain of custody across clinical products.
Whole plant versus HCl risk	Formulations are chemically and pharmacokinetically non equivalent, and severe cases involve both purified products and plant material.	Head to head analytical and clinical safety data.
Delayed events	Psychiatric and cardiac effects can extend beyond the acute visionary phase.	Prospective post acute surveillance with standardized adverse event definitions.
Predictors of TdP	General risk factors are known, but serious ibogaine events remain too sparse and heterogeneous for reliable prediction.	Large multicenter safety registry or trials with denominator data and complete ECG, electrolyte, product and medication information.
QT prolongation versus arrhythmia	Marked QT prolongation is common in at least one monitored cohort, while TdP was absent in that small study and present in case reports.	Data connecting magnitude, morphology, pauses, ectopy, concentration and patient context to actual arrhythmia events.
Staffing and facility requirements	Controlled settings with trained personnel and cardiac monitoring are consistently associated with more complete detection and management.	Comparative evidence identifying minimum safe capabilities and staffing without relying on anecdote.
Longitudinal outcomes	Withdrawal and craving signals are present.	Controlled data on relapse, mortality, functioning, psychiatric outcomes and comparative effectiveness beyond the early post treatment period.
Post detoxification overdose	General OUD literature shows danger after tolerance loss.	Ibogaine specific longitudinal overdose data and evaluation of linkage to MOUD and overdose prevention.
Adverse event underreporting	Case literature and reviews repeatedly note incomplete reporting and uncertain denominators.	Prospective registry with standardized event capture, severity, causality assessment, formulation and time course.
Fentanyl era applicability	Most classic ibogaine detoxification studies predate widespread fentanyl exposure.	Modern OUD cohorts with verified fentanyl exposure, withdrawal characterization and post treatment outcomes.
Movement sensitive nausea and vestibular support	Peer reviewed clinical observation documents movement induced vomiting and transient vestibulocerebellar dysfunction; general vestibular physiology supports a motion sensitive emetic pathway.	Prospective measurement of vertigo, motion sensitivity, nausea severity, and whether structured low movement care reduces symptoms or complications.
Supportive care and nursing workload	Severe ataxia, vomiting, prolonged immobility and assisted toileting are documented.	Prospective data on falls, aspiration, staffing burden, toileting, skin injury, hydration support and patient experience.
Antiemetic strategy	Nausea and vomiting are common and several common antiemetics carry QT, sedation or interaction concerns.	Comparative ibogaine specific antiemetic safety and efficacy data.
Micronutrient and magnesium strategy	General alcohol medicine supports targeted thiamine and correction of magnesium deficiency; MISTIC used magnesium coadministration.	Controlled evidence that prophylactic magnesium or any banana bag style protocol changes ibogaine cardiac outcomes.
Post discharge surveillance	Delayed cardiac and psychiatric events are documented, but follow up methods vary.	Prospective studies defining symptom, ECG, sleep and psychiatric follow up intervals after discharge.
Facilitator support model	Phenomenology and community practice describe sensory, relational and physical vulnerability.	Prospective evaluation of specific support practices, participant experience, dignity, trust, and adverse event detection.

In practice

Explain uncertainty in relation to the question being asked. A participant may need to know what is unknown about benefit or risk; a team may need to know why a practice is provisional. Record the limit and the resulting decision rather than filling the gap with confidence or an inherited rule.

Evidence gap · Project synthesis / non peer reviewed · Practice confidence: Evidence gap

Knuijver (2022); Knuijver (2024); Ona (2022) · 1 more

View Evidence 5 sources

Continue Through the Global Competencies

Participant reading path Link to this topic

Deferral, Reassessment, and Alternative Care Pathway

Distinguish temporary delay, specialty review, setting mismatch, referral, and emergency disposition.

Distinguish temporary deferral, specialty review, need for a higher-acuity setting, alternative care, and emergency referral. Do not pressure the participant to conceal information to preserve a scheduled treatment.

Responsibility: Facilitator · Program / system
Applies in: Multiple settings

A screening process is incomplete if it only explains who can proceed. Programs also need a humane process for “not today,” “not in this setting,” and “not until this is evaluated.” Earlier provider standards explicitly called for a rejection process; this lens reframes that as deferral and referral because many risks are temporary or setting-dependent rather than permanent characteristics of the person.

Disposition	Meaning	Required communication
Proceed	Current information supports proceeding within the capability of the setting.	Document the rationale and remaining watch points.
Temporary deferral	A reversible problem remains: acute illness, intoxication, uncontrolled withdrawal, electrolyte abnormality, incomplete records, medication transition, dehydration, or another correctable issue.	Name what must be resolved and who owns follow-up. Give the person a realistic reassessment path.
Specialty review before decision	The risk cannot be responsibly interpreted by the current team alone.	Obtain cardiology, toxicology, psychiatry, addiction medicine, or other consultation before deciding.
Different setting required	The participant may be appropriate for treatment, but the current site cannot safely manage the anticipated risk.	Refer to a setting with the required monitoring, staffing, or emergency capability.
Alternative care now	Another treatment is more urgent or better supported for the immediate problem.	Provide referral rather than leaving the person with a simple rejection.
Emergency evaluation	The screening process identifies an active emergency.	Stop the elective treatment pathway and activate appropriate emergency care.

PRACTICE POSITION: a deferral should explain the reason in plain language, distinguish temporary from persistent concerns, document urgent risks, offer appropriate alternatives or referrals, and avoid shame. No person should be encouraged to hide medication use, substance exposure, or symptoms in order to “pass” screening.

The literature supports structured cardiovascular, medical, neurological, substance, and psychiatric screening. What it still lacks is a validated composite eligibility score or a universal diagnosis list that predicts serious ibogaine toxicity on its own.

In practice

A deferral conversation deserves time and privacy. Acknowledge the practical and emotional investment without bargaining away the clinical concern. Explain what is known, what remains uncertain, and whether the issue can be reassessed. Give a written next step and identify the person or service responsible for it.

Expert practice · Project synthesis / non peer reviewed · Practice confidence: Expert Operational Practice

Knuijver (2022); Alper (2012); Rocha (2023) · 2 more

View Evidence 6 sources

Continue Through the Global Competencies

See how this is explained to participants Link to this topic

Team responsibilities by phase

Candidate Evaluation

Clinical goal	Information required	Main risks	Required decisions	Documentation
Build a defensible picture of medical, psychiatric, substance, medication, and social context before deciding whether treatment should proceed.	History, ECG, substance timeline, medication list, relevant labs, mental status, prior reactions, collateral information where appropriate.	Unrecognized cardiovascular disease, withdrawal complications, interacting agents, impaired capacity, unstable psychiatric or medical state.	Proceed, seek additional evaluation, postpone, or determine that the setting cannot safely meet the person’s needs.	Screening rationale, findings, consultations, unresolved questions, and decision authority.

Pre Treatment Optimization

Clinical goal	Information required	Main risks	Required decisions	Documentation
Reduce modifiable risk and confirm that a person who may be broadly eligible is physiologically and psychologically ready on the planned day.	Hydration, nutrition, withdrawal status, recent substance use, sleep, current symptoms, medication plan, updated ECG or labs when clinically indicated.	Electrolyte loss, intoxication, unstable withdrawal, vomiting, acute illness, medication interaction, changing mental status.	Correct or stabilize reversible concerns, obtain specialty input, or postpone.	What changed from screening, what was corrected, remaining risk, and authorization to proceed.

Practitioner and Facilitator Knowledge Core

Facilitator Competency Matrix: Know, Recognize, Support, Escalate

In practice

Historical and Cultural Orientation for Facilitators

Responsibility Level Tags

In practice

Candidate Evaluation

Building the Participant History and Clinical Context

Bring the findings together

Voluntariness, Motivation, and Expectation Setting

In practice

Preparation as Participant Skill Building

In practice

Informed Consent

Session Consent and Vulnerability Planning

In practice

Participant Rights, Advocacy, Complaints, and Grievance

Participant rights

Information about your care

Choice and questions

Privacy and records

Complaints and accountability

Communication assistance

Leaving treatment

What Competent Care Should Look Like From the Participant Side

In practice

Provider Transparency Profile

Separate Optional Consent From Treatment Consent

In practice

Baseline Clinical Examination and Functional Reference

In practice

Arrival and Secondary Verification

In practice

Substance Use History

Alcohol Use Disorder: New Direct Human Data

In practice

Medication and Interaction Review

In practice

Cardiovascular Evaluation

In practice

Cardiac Risk Modifiers

In practice

Laboratory Evaluation

In practice

Physiological Readiness

In practice

Nutrition, Hydration, Bowel Function, and Micronutrient Support

Ginger and Other Simple Comfort Measures

Psychiatric and Neurobehavioral Evaluation

In practice

Travel, Cross-Border, and Return-Environment Readiness

In practice

Special Populations

In practice

Supportive and Emergency Medications

Medications and equipment to have ready

Torsades and prolonged QT

Bradycardia and perfusion

Seizures and GABA mediated treatment

Persistent vomiting and antiemetic selection

Serotonin toxicity, agitation, and withdrawal

Orders, reassessment, and handoff

In practice

Safety Relevant Pharmacology and Pharmacokinetics

In practice

Observed Human Exposure and Dose Context

In practice

Practice Landscape, Not Dosing Guidance: Flood, Split, Extended, and Repeat-Dose Models

In practice

Product Identity and Formulation

Ethical Traceability and Provenance

In practice

Cardiac Mechanism

In practice

Traditional and Community Knowledge

In practice

Evidence Gaps

Unresolved research questions

In practice

Deferral, Reassessment, and Alternative Care Pathway